TOPIRAMATE- topiramate tablet Proficient Rx LP

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information meeded to use TOPIRAMATE tablets, USP safely and effectively. See full prescribing information for TOPIRAMATE tablets, USP. TOPIRAMATE tablets USP, for oral Use. Initial U.S. Approval: 1996 DEFERT MADE OF FEATURE FOR THE ADDR FLAMMER FLAMMER FLAMMERS

······ RECENT MAIOR CHANGES ······· Warnings and Precautions, Visual Field Defects (5.2) 01/2014

INDICATIONS AND USAGE Topiramate tablets USP is an antiepileptic (AED) agent indicated for:

Monotherapy epilepsy: Initial monotherapy in patients ≥ 2 years of age with partial onset or primary
generalized tonic-clonic seburuse; (11)
 Adjunctive therapy replepsy: Adjunctive therapy for adults and pediatric patients; lot to 16 years of age)
with partial onset sebures or primary generalized tonic-clonic seburuse; and in patients ≥2 years of
age with setures associated with tennor Gastaut sprimore (LGS) (12)

DOSAGE AND ADMINISTRATION See DOSAGE AND ADMINISTRATION, Epilepsy: Monotherapy and Adjunctive Therapy Use for additional details_

	Initial Dose	Titration	Recommended Dose
Epilepsy monotherapy:_ children 2to<10years_(2.1)	25mg/day administered nightly for the first week	The dosage should betitratedover5-7 weeks	Daily doses in two divided doses based on weight(Table2)
Eplepsy monotherapy: adults and pediatric patients 210 years (2.1)	50mg/day in two divided doses	The dosage should be increased weekly by increments of 50mg for the first 4 weeks then100mgfor weeks 5to6.	400 mg/day in two divided doses
Epilepsy adjunctive_therapy ;adults with partial onset seizures or LGS(2:1)	25to50mg/day	The dosage should be increased weekly to an effective dose by incrementsof25to50mg.	200–400 mg/day in two divided doses
Epliepsy adjunctive therapy: adults with primary generalized tonic- clonic seizures(2.1)	25to50mg/day	The dosage should be increased weekly to an effective dose by incrementsof25to50mg.	400 mg/day in two divided doses
Eplepsy adjunctive therapy; pediatric Patients with partial, onset secures, primary generalized tonic- clonic seizures or LGS(186Errorf Hyperlink reference not valid.	25mg/day(or less, based on a range of1to3mg/kg/day) nightly for the first week	The dosage should beincreasedat1-or 2-weekintervalsby incrementsof1to3 mg/kg/day(administered in two divided doses).Dose titration should be guided by clinical outcome.	5to9mg/kg/day in two divided doses

None (4)

WARNINGS AND PRECAUTIONS

- Acute myopia and secondray angle closure gluxicoms: Untreated elevated intraocular pressure can
 Conterminity of the secondray angle closure gluxicoms: Untreated elevated intraocular pressure can
 topramate as regolity as possible (151) international increases symptoms is discontinuation of
 topramate as regolity as possible (151) international increases symptoms is discontinuation of
 topramate as regolity as possible (150) international increases and provide international increases
 topramate as regolity as possible (150) international increases and provide temperature,
 especially in pediatric patients (153)
 Metabolic addobis: Baseline and periodic measurement of serum bicahonate is recommended.
 Suicital behavior and idention: interpleptic drugs increase the risk of suicital behavior or ideaton
 (153)
 Cognitisentemorpsychiatric: Topriamate may cause cognitive dysfurction: Patients should use caution
 (153)
 Fetal Toxicity: Topriamate use during pregnancy can cause cells flan and/or patients.
 Prestammental description without control and the pregnancy can cause cells
 Patients with intome errors of metabolism or reduced microchondrial activity may have an increased
 player and metapholisty associated during topriamate valproc call use:
 Patients with intome errors of metabolism or advocir or elevation
 players produced activity and advoluted (111)
 Hyperammenenia.
 Hyperammenenia descriptional advoluted (111)
 Hyperaminese and encephologial and without concornation advolute causion
 or in patients on a lettogenic det should be avoided (111)
 Hyperaminese and encephologial and without concornation during topriamate restament with
 concombart valproc call use (112)

ADVERSE REACTIONS The most common (>10% more frequent than placebo or low-dose topiramate in monothernay) advesse reactions at recommended dosing in adult and pediatric controlled, pellepsy fulficial traits were paresthesia, anorexia, weight decrease, speech floorder related speech problem, fatigue, dizziess, somolence, nervourses, spychomot solwing, abnormal vision, and fever. (Forof Hyperfink

somolence, nervousness, psychomotor slowing, annomai volan, and in-article and a sector of the secto DRUG INTERACTIONS nary of antiepileptic drug (AED) interactions with topiramate tablets (7.1)

AED Co-administered	AED Concentration	Topiramate Concentration
Phenytoin	NCor25%increase ^a	48%decrease
Carbamazepine(CBZ)	NC	40%decrease
CBZepoxide ^b	NC	NE
Valproic acid	11%decrease	14%decrease
Phenobarbital	NC	NE
Primidone	NC	NE
Lamotrigine	NCatTPM dosesupto400 mg/day	13%decrease

- Oral contraceptives: Decreased contraceptive efficacy and increased breakthrough bleeding should be considered, especially at doese greater than 700 mg/asy (7.3) University of the contract of the contract of the contract backs (7.4)
 Utilium invelse blood be monothered when co-administered with high-does contraminate tablets (7.5)
 Other carbonic anhydrase inhibitors: Monitor the patient for the appearance or worsening of metabolis acidosis (7.6)
- USE IN SPECIFIC POPULATIONS ...
- Renal innoviment: in renally making patients of a statistical clearance less than 70 mL/min(1.73 m²), Renal innoviment: in renally making patients of the statistical clearance less than 70 mL/min(1.73 m²), Patients undergoing hemotalayists: Topiramate jasma concertration during hemotalayist; (2.6) rescassing to avoid rapid drogs in topinamate jasma concertration during hemotalayist; (2.6) Renally and the statistical clearance in the statistin the statistical clearance in the statistical clearance in the

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 4/2022

FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Monotherapy Epilepsy 1.2 Adjunctive Therapy Epilepsy 2 DOSAGE AND ADMINISTRATION

- DOSABLE ARU ADMINISTRATION
 2.1 Epilepsy
 2.4 Palents with Renal Impairment
 2.5 Gerärtric Patients (Ages 65 Years and Over)
 2.6 Palents Windergoing Hemodialysis
 2.7 Palents with Hepatic Disease
 BOSAGE FORMS AND STREMGTHS
 CONTRAINDOCATIONS
 5.1 Anrum Noviba and Secondary Angle Closure
 5.1 Anrum Noviba and Secondary Angle Closure

- UDI INTRAINOL CALIDREATIONS
 VARAINIGS AND PRECAUTIONS
 VARAINIGS AND PRECAUTIONS
 Visual Field Defects
 Visual Field
 Visual Field
 Visual
 Visual Field
 Visual Field

- 5.14 Adjustment of Dose in Renal Failure 5.15 Decreased Hepatic Function 5.16 Monitoring: Laboratory Tests 6 **ADVERSE REACTIONS** 6.1 Clinical Trial Experience 6.2 Postmarketing and Other Experience **7 DRUG INTERACTIONS** 7.1 Antieolientic Drugs
- 7.2 CNS Depressants
- 7.3 Oral Contraceptives 7.4 Metformin 7.5 Lithium
- 7.6 Other Carbonic Anhydrase Inhibitors 8 USE IN SPECIFIC POPULATIONS
- 8.1 Pregnancy 8.2 Labor and Delivery
- 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Race and Gender Effect

- 8.7 Renal Impairment 8.8 Patients Undergoing Hemodialysis 8.9 Women of Childbearing Potential 10 OVERDOSAGE

- 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics

- 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinopenesis, Mutagenesis and Impairment of Fertility 14 CLINICAL STUDIES 14.1 Monotherapy Epilepsy Controlled Trials 14.2 Adjunctive Therapy Epilepsy Controlled Trials 16.1 How SupPLIED/STORAGE AND HANDLING 16.1 How SupPlieD

- 16.1 How Supplied 16.2 Storage and Handling 17 PATIENT COUNSELING INFORMATION Services or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Monotherapy Epilepsy

Topiramate tablets USP are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see Clinical converted of the control of the set of the s Studies (14.1)].

1.2 Adjunctive Therapy Epilepsy

Topiramate tablets USP are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic clonic seizures, and in patients 2 years of age and older with seizures associated w Lennox-Gastaut syndrome (see *Clinical Studies* (14.2)). with

2 DOSAGE AND ADMINISTRATION

2.1 Epilepsy

It is not necessary to monitor topiramate plasma concentrations to optimize topiramate therapy.

On occasion, the addition of topiramate to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and/or carabmazepine during adjunctive therapy with topiramate may require adjustment of the dose of topiramate.

Because of the bitter taste, tablets should not be broken.

Topiramate tablets USP can be taken without regard to meals

Monotherapy Use

Adults and Pediatric Patients 10 Years and Older

The recommended dose for topiramate monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. Approximately 58% of patients randomized to 400 mg/day achieved this maximal dose in the monotherapy controlled trial; the mean dose achieved in the trial was 275 mg/day. The dose should be achieved by thration according to the following schedule (Tpible 1):

Table 1: Monotherapy Titration Schedule for Adults and Pediatric Patients 10

	Morning Dose	Evening Dose
Week 1	25 mg	25 mg
Week 2	50 mg	50 mg
Week 3	75 mg	75 mg
Week 4	100 mg	100 mg
Week 5	150 mg	150 mg
Week 6	200 mg	200 mg

Children Ages 2 to <10 Years

Dosing of topiramate as initial monotherapy in children 2 to < 10 years of age with partial onset or primary generalized tonic-clonic seizures was based on a pharmacometric bridging approach *[see Clinical Studies (14.1)*]

pharmacometric bridging approach (see Clinical Studies (14.1)) Dosing in patients 2 to <10 years is based on weight. During the thration period, the initial dose of topiramate should be 25 mg/day administered nightly for the first week. Based upon toberability, the dosage can be increased to 50 mg/day (25 mg twice dally) in the second week. Dosage can be increased by 25–50 mg/day each subsequent week as tolerated. Thration to the minimum maintenance dose should be attempted over 5–7 weeks of the total thration period. Based upon tolerability and secure control, additional 25–50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight (Table 2).

Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to <10 Years

Weight (kg)	Total Daily Dose (mg/day)* Minimum Maintenance Dose	Total Daily Dose (mg/day)* Maximum Maintenance Dose
Up to 11	150	250
12 - 22	200	300
23 - 31	200	350
32 - 38	250	350
Greater than 38	250	400
*Administered in	two equally divided doses	

Adjunctive Therapy Use

Adults 17 Years of Age and Over - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

Conc Secures, or Lennox-Gastaut Syndrome The recommended total day dose of topiamate as adjunctive therapy in adults with partial onset seizures is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. It is recommended that therapy be initiated at 25 to 50 mg/day followed by titration to an effective dose in increments of 25 to 50 mg/day every week. Titrating in increments of 25 mg/day every week titrating in poses above 400 mg/day (dos) 000 or 1,000 mg/day) have not been shown to improve responses in dose-response studies in adults with partial onset secures. Daily doses above 1,600 m jave not been studied.

In the study of primary generalized tonic-clonic seizures, the initial titration rate was slower than in previous studies; the assigned dose was reached at the end of 8 weeks [see Clinical Studies (14.1)]

Pediatric Patients Ages 2 – 16 Years – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

Conci Sezures, or Lennox-Gastaut Syndrome The recommended total daly dose of Topiramate as adjunctive therapy for pediatric patients with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Thration should begin at 25 mg/kg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be ncreased at 1- or 2-week intervas by increments of 1 to 3 mg/kg/day (daministered in two divided doses), to achieve optimal clinical response. Dose thration should be guided by clinical outcome.

In the study of primary generalized tonic-clonic seizures, the initial titration rate was slower than in previous studies; the assigned dose of 6 mg/kg/day was reached at the end of 8 weeks [see Clinical Studies [14.1]].

2.4 Patients with Renal Impairment

In renally impaired subjects (creatinine clearance less than 70 mL/min/1.73 m²), one-half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.

2.5 Geriatric Patients (Ages 65 Years and Over)

Dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate <70 mL/min/1.73 m2) is evident [see Clinical Pharmacology (12.3)].

2.6 Patients Undergoing Hemodialysis

2.6 Patients Undergoing Hemociaaysis
Topiramate is cleared by hemocialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause toppramate concentration to fal below that required to maintain an anti-secure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of toppramate in the patient being dialyzed.

2.7 Patients with Hepatic Disease

In hepatically impaired patients, topiramate plasma concentrations may be increased. The mechanism is not well understood.

Topiramate tablets USP are available in the following strengths and colors: 25 mg, White colored, circular, biconvex film-coated tablets, debossed with "122" on one side and "C" on the other side 50 mg, Light orange colored, circular, biconvex, film-coated tablets, debossed with "123" on one side and "C" on the other side.

100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side. 200 mg, Pink colored, capsule shaped, biconvex, film-coated tablets, debossed with "125" on one side and "Cipla" on other side.

4 CONTRAINDICATIONS Non

5 WARNINGS AND PRECAUTIONS

5.1 Acute Myopia and Secondary Angle Closure Glaucoma

5.1 Acute Myopia and Secondary Angle Closure Glaucoma
A syndrome constitut of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate. Symptoms include acute onset of decreased visual acuty and/or ocuter pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemik (redness), and increased intraocuter pressure. Mydrass may or may not be present. This syndrome may be associated with supracillary effusion resulting in anterior displacement of the lens and risk with secondary angle closure glaucoma. Symptoms typical occur within 1 month of Indiant or displacement of presents and the syndrase may be been reported in pediatric patients as well as adust. The primary treatment to reverse symptoms is discontinuation of topiramate. any bu forsition, adults and for any and recours the fuel treating physician. Other measures, in conjunction with discontinuation of topiramate, may be fight.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

5.2 Visual Field Defects

Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trails and in post marketing experience in patients receiving topiramate. In clinical trails, most of these events were reversible after topiramete decontinuation. If visual problems occur at any time during topiramate treatment, consideration should be given to discontung the drug.

5.3 Oligohidrosis and Hyperthermia

Olgohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with topiramate use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

The majority of the reports have been in pediatric patients, Patients, especially pediatric patients, treated with topiramate should be monitored closely for evidence of decreased eventing and increased body temperature, especially in hot weather. Cauton should be used when topiramate is prescribed with other drugs that predspose patients to heat-related disorders; these drugs include, but are not limked to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.

5.4 Metabolic Acidosis

Jav metadouk, Ak NoSB Hyperchlorenki, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkabasis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such electrobyte mibance has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis occurs aery in treatment alhologi cases can occur at any time during treatment. Bicarbonate decrements are usually mil-moderate (average decrease of d metabolic acidosis occurs aery to mo in solutior and a paroxymitathe is molecular in during treatment. Bicarbonate docrements are usually mil-moderate (average decrease ubil igi uestireti. Si ka uonae vest enersi sa e susay minimuo a e veri seguest e of 4 mEqL a daly dosse of 400 mg in adults and a approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10 mEqL. Conditions or threapies that predispose potients to actioosis (such as renal disease, severe respiratory disorders; status epilepikus; diarrhea, ketogenic det; of topiramate.

specific drugs) may be additive to the bicarbonate lowering effects of topiramate. Some manifestations of acute or chronic metabolic acidosis may include hypervenitation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelee including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may horease the risk for nephrolithais or inperioracimosis, and may also result in osteomabacia (for fracta control the predict patients) and/or one severe sequelee including cardiac arrhythmia predict patients) and/or one severe sequelee including cardiac arrhythmia predict patients) and/or one severe sequelee tracks for enclution in growth rate may eventually decrease the maximal height achieved. The effect of Topiramate on growth and bone-related sequelee has not been systematically investigated in long-term, pacebo-controller trisks. Long-term, open-label treatment of infants,toddlers, with intractable partial epilepsy, for up to 1 year, showed reductions from baseline in 2 SCORES for length, weight, and head circumference compared to age and sex-matched normative data, although these patients with epilepsy are likely to have different growth rates than normal infants. Reductions in 2 SCORES for length and weight were correlated to the degree of acidosis das cause metabolic acidosis in the neonate from possible transfer of topiramate to the facus (acidosis during pregnancy can possibly produce adverse effects on the fetus and might also cause metabolic acidosis (5.7) and Use in Specific Populations (8.1)). Epilepsy

Adult nationts

Adult patients in adults, the incidence of persistent treatment-emergent decreases in serum bicarbonate (levels of <20 mEq/L at two consecutive visits or at the final visit) in controlled clinical trius for adjunctive treatment of eplepsy was 32% for 400 mg/day, and 1% for piacebo. Metabolic actiosis has been observed at doses as low as 50 mg/day. The indicance of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L and >5 mEq/L decrease from pretreatment) in the adjunctive therapy treatment-emergent decreases in serum bicarbonate in adult patients (216 years of treatment-emergent decreases in serum bicarbonate in adult patients (216 years of treatment-emergent decreases in serum bicarbonate in adult patients (216 years of 12% for 400 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17 mEq/L, and >5 mEq/L decrease from pretreatment) in this trial for adults was 3% for 50 mg/day and 6% for placedly abnormally two serum bicarbonate have not been systematically evaluated at daily doses greater than 400 mg/day. Ex-Bedratic neiter for

Pediatric patients

Treated patients (2 to 16 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adjunctive treatment of Lennox-Gastaut syndrome or refractory partial onest secures was 67% for topiramate(at approximately 6 mg/krg(day), and 10% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e. absolute value – 17 mEg(L and >5 mEg(L decrease from pretreatment) in these trials was 11% for topiramate and 0% for placebo. Cases of moderately server metabolic actions have been reported in platents as young as 5 months old, especially at daily doses above 5 mg/krg(day.

Although not approved for use in patients under 2 years of age with partial onset Akhough not approved for use in patients under 2 years of age with partial onset seizures, a controlled trial that examined this population revealed that topiramete produced a metabolic acidosis that is notably greater in magnitude than that observed in controlled trials in older children and adults. The mean treatment difference (25 mg/kg/dgv topiramate-placebo) was -59 mEq.L for bicarbonate. The incidence of on metabolic acidosis (leftend by a serum bicarbonate-20 mEq.L) was 0% for placekolnce of markedly abnormal changes (i.e., <17 mEqL and >5 mEqL decrease from baseline of 220 mEqLV was 0% for placebo, 4% for 57 mg/kg/dgv, 5% for 15 mg/kg/dgv, gas for serue (14 mg/kg) and 5% for 25 mg/kg/dgv, 5% for 15 mg/kg/dgv, and 5% for 25 mg/kg/day (see Use in Specific Populations (8-4)).

The 2-mingraphy presents for bit 2-mingraphy (equations) (even). In pediatric patients (6 to 15 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in the eplepsy controlled clinical trial for monotherapy ways % for 50 milday and 25% for 400 mig/day. The nickence of a markedly abnormally two serum bicarbonate (i.e., absolute value <17 mEqL and > mEqL decrease from pertendinent) in this trial ways 1% for 50 milday and 6% for 5 400

Measurement of Serum Bicarbonate in Epilepsy Patients

Measurement of baseline and periodic serum biacarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alial treatment should be considered.

5.5 Suicidal Behavior and Ideation

Anticipileptic drugs (AEDs), including topiramate, increase the risk of suicidal thoughts o behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 piacebo-controlled cinical trails (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately where the risk (alusced Relative Risk 18, 95% ci-12, 27) of suicidal thinking or behavior compared to patients randomized to placebo. In these trails, which had a midain treatment duration of 12 weeks. The estimated indicance rate of suicidal behavior or ideation among 27, 863 AED-treated patients was 0.43%, compared to 0.24% among 16.029 placebo-treated patients representing an increase of approximately one case of suicidal thinking or behavior for every S30 patients treated. There were forus valicidies in drug-treated patients in the trails and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect

on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk vapiles to al AEDs used for any indication. The risk idd not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 4 shows absolute and relative risk by indication for all evaluated AEDs

Table 4: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

Indication	Placebo Patients with Events per 1000 Patients	Drug Patients with Events per 1000 Patients	Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients	Risk Difference: Additional Drug Patients with Events per 1000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9
	•	•		

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing topiramate or any other AED must balance the risk of Anyone considering prescribing topiramate or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated liness. Epilepsy and many othe linesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the liness being treated.

These being utexts. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

5.6 Cognitive/Neuropsychiatric Adverse Reaction

Adverse reactions most often associated with the use of topiramate were related to the Adverse reactions most often associated with the use of topic anade were readed to on certral nervous system and were observed in epilepsy populations. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., confusion, psychomotor solwing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-inding difficulties); 2) Psychiatrichebavioral disturbances (e.g., depression or mood problems); and 3) Somnolence or fatigue.

Adult Patients

Cognitive-Related Dysfunction

The majority of cognitive-related adverse reactions were mild to moderate in severity, and they frequently occurred in isolation. Rapid thration rate and higher initial dose were associated with higher incidences of these reactions. Many of these reactions contributed to withdrawal from treatment [see Adverse Reactions (6)].

contributed to withdrawal from treatment [see Adverse Reactions (6)]. In the add-on epilepsy controlled trials (using rapid titration such as 100-200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 55% for 600 and 1.000 mg/day, and 14% for placebo. These doss-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse reactions in the tratation phase had a dos-related recurrence of these reactions in the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for topiramate50 mg/day and one or more cognitiv 26% for 400 mg/day

Psychiatric/Behavioral Disturbances

Psychiatric/behavioral disturbances (depression or mood) were dose-related for epilepsy population [see Warnings and Precautions (5.5)].

Somnolence/Fatique

Sominone and fatigue were the adverse reactions most frequently reported during clinical trials of topiramate for adjunctive epilepsy. For the adjunctive epilepsy population, the incidence of somnoince durin durin differ substantially between 200 mg/day and 1.000 mg/day, but the incidence of fatigue was dose-related and increased at dosages above 400 mg/day. For the monotherapy epilepsy population in the 50 mg/day and 400 mg/day groups, the incidence of somnoince was dose-related (9% for the 50 mg/day group and 15% for the 400 mg/day group) and the incidence of fatigue was comparable in both treatment groups (14% each).

Additional nonspecific CNS events commonly observed with topiramate in the add-on epilepsy population included dizziness or ataxia.

Pediatric Patients

Pediatric Patients In double-bild adjunctive therapy and monotherapy epilepsy clinical studies, the incidences of cognitive/neuropsychiatric adverse reactions in pediatric patients were generally lower than observed in adults. These reactions included psychomotor slowing, difficulty with concentration/attention, speech disorders/related speech problems, and language problems. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-bild studies were somnolence and fatigue. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-bild studies were somnolence and fatigue heradache, dizziness, amorexia, and somnolence.

No patients discontinued treatment due to any adverse reactions in the adjunctive epilepsy double-bind trials. In the monotherapy epilepsy double-bind trial, 1 pediatric patient (2%) in the 50 mg/day group and 7 pediatric patients (12%) in the 400 mg/day group discontinued treatment due to any adverse reactions. The most common adverse reaction associated with discontinuation of theragy was difficulty with concentration/attention; all occurred in the 400 mg/day group.

5.7 Fetal Toxicity

Topiramate can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate *in utero* have an increased risk for cleft lip and/or cleft palate (oral clefts). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural maformations, including cranificatial defects, and reduced fetal weights occurred in offspring [see Use in Specific Populations (8.1)].

Onspiring See Use in Specific Populations (a.1), Consider the benefits and the risks of topiramate when administering this drug in women of childbearing potential, particularly when topiramate is considered for a condition on tusually associated with permanent highry or death (see Use in Specific Populations (8.9) and Patient Counseling Information(ErrorI Hyperlink reference not valid).], Topiramate should be used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) and (8.9)].

5.8 Withdrawal of Antiepileptic Drugs (AEDs)

In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including topiramate, should be gradually withdrawn to minimze the potential for seizures or increased seizure frequency [see Clinical Studies (14)]. In situations where rapid withdrawal of Topiramate is medically required, appropriate monitoring is recommended.

5.9 Sudden Unexplained Death in Epilepsy (SUDEP)

During the course of premarketing development of topiramate tablets, 10 sudden and unexplained deaths were recorded among a cohort of treated patients (2796 subject years of exposure). This represents an incidence of 0.0035 deaths per patient year. Athough this rate exceeds that expected in a heathy population matched for age and esex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving topiramate tablets (ranging from 0.0005 for the general population of patients with epilepsy. to .003 for a chical trial population similar to that in the topiramate tablets program, to 0.005 for patients with refractory epilepsy).

5.10 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use)

Hyperammonemia/Encephalopathy Without Concomitant Valproic Acid (VPA) Topiamate treatment has product ad hyperamonemia in a clinical investigational program in very young pediatric patients (1 to 24 months) who were treated with adjunctive topiamate for partial conset epilepsy (24 %offs) produced). Diffs for 5 mg/kg/ 0% for 15 mg/kg/day, 9% for 25 mg/kg/day). In some patients, ammonia was increased (25% above upper limit of normal). The hyperammonemia associated topiamate treatment occurred with and without enceyhate with effective occurred trials and in an open-label, extension trial of financia. /kg/day

uses and in an open-adve, exception in and or induct window with fer actory (papely). Dose-related hyper-momenia was observed in the extension trial in pediatric patients up to 2 years old. Clinical symptoms of hyperarminonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. Topiramate tablet is not approved as adjunctive treatment of partial onset seizures in pediatric patients less than 2 years old.

Hyperammonemia with and without encephalopathy has also been observed in post-

marketing reports in patients who were taking topiramate without concomitant valproic acid (VPA).

Hyperammonemia/Encephalopathy With Concomitant Valproic Acid (VPA)

Ingreatinitatienterinateinetarium y man contentinatien variautus redutterinatienterinateinetarium variante and varianteria enterinatienter

Although topiramate tablet is not indicated for use in infants/toddlers (1-24 months), Topiramate with concomitant VPA clearly produced a dose-related increase in the Topramate with concomitant VPA clearly produced a dose-related increase in the incidence of treatment-emergent hyperammonemia (above the upper limit of norma). 0% for placebo, 12% for 5 mg/kg/day, 7% for 15 mg/kg/day, 17% for 25 mg/kg/day) in an investigational program. Marked() increased, dose-related hyperammonemia (0% for placebo and 5 mg/kg/day, 7% for 15 mg/kg/day, 8% for 25 mg/kg/day) also occurred in these infants/roddlers. Dose-related hyperammonemia was similarly observed in a long-term extension trial in these very young, pediatric patients [see Use h Specific Populations (8.4)].

Hyperammonemia with and without encephalopathy has also been observed in post-marketing reports in patients taking topiramate with VPA.

The hyperammonemia associated with Topiramate treatment appears to be more common when topiramate is used concomitantly with VPA.

Monitoring for Hyperammonemia

Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity be at an increased risk for hyperanmonemia with or without encephalopathy. Altho not studied, Toparamate treatment or an interaction of concomitant topiramate and valprok acid treatment may exacerbate existing defects or unmask deficiencies in susceptible persons.

In patients who develop unexplained lethargy, vomiting, or changes in mental status associated with any topiramate treatment, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.

5.11 Kidnev Stones

5.11 Kidney Stones A total of 32/2066 (1.5%) of adults exposed to topiramate during its adjunctive epileps therapy development reported the occurrence of kidney stones, an incidence about 2 4 times greater than expected in a similar, untreaded population. In the double-bind monotherapy epilepsy study, a total of 4/319 (1.3%) of adults exposed to topiramate reported the occurrence of kidney stones. As a the general population, the incidence stone formation among topiramate-treated patients was higher in men. Köney stones have abo been reported in pediatir patients taking topiramate for epilepsy.

During long-term (up to 1 year) topiamate treatment in an open-label extension study of 284 pediatric patients 1-24 months od with epilepsy. 7% developed kitney or bladds stones that were diagnosed clinically or by sonogram. Topiamate tablet is not approve for pediatric patients less than 2 years old *[see Use in Specific Populations (8.4)]*.

run peuauric patients less than 2 years old [see Use n 5 pecific Populations (8.4)]. An explanation for the association of top/amate tablets and kindney stones may le in the fact that top/amate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor, fact and the second and the second and the princh standard second and the princh sensing uninary phi (see Warnings and Precautions (5.4)). The concommant use of top/amate tablets with any other drug producing metabolic activacianimistant use of top/amate tablets with any other drug producing metabolic activacianimist the second secon

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation.

5.12 Hypothermia with Concomitant Valproic Acid (VPA) Use

5.12 Hypotherma with Concentiant Vapproc Acid (VPA) Use Hypothermia, defined as an unithentional drop in body core temperature to <35°C (95°F). has been reported in association with topiramate use with concomtant valproic acid (VPA) both in conjunction with thyperammonemia and in the absence of hyperammonemia. This adverse reaction in patients using concomtant topiramate and valproate can occur after starting topfarmate transmit or after increasing the daily dose of topiramate (see Drug Interactions (7.1)). Consideration should be given to stopping topiramate or valproate in patients with devide hypotherma, which mays and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood ammonia levels.

5.13 Paresthesia

Any paresthesia usually inging of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of topiamate tablets. Paresthesia was more frequently reported in the monotherapy epilepsy trials and migrahe prophylaxis trials than in the adjunctive therapy epilepsy trials. In the majority of instances, paresthesia did not lead to treatment discontinuation.

5.14 Adjustment of Dose in Renal Failure

The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function (see Dosage and Administration (2.4)).

5.15 Decreased Hepatic Function

In hepatically impaired patients, topiramate tablets should be administered with caution as the clearance of topiramate may be decreased [see Dosage and Administration (2.7)]

5.16 Monitoring: Laboratory Tests

Topiramate treatment was associated with changes in several clinical laboratory analytes in randomized, double-blind, placebo-controlled studies.

Topiamate treatment causes non-anion gap, hyperchloremic metabolic acidosis manifested by a decrease in serum bicarbonate and an increase in serum chloride. Measurement of baseline and periodic serum bicarbonate during topiramate tablets treatment is recommended *[see Warnings and Precautions [5.4]]*.

Topiramate tablets treatment with or without concomitant valproic acid (VPA) can cause hyperammonemia with or without encephalopathy [see Warnings and Precautions hyperar (5.10)].

L-LAUJI. The clinical significance of decreased serum bicarbonate and associated increased serum chloride reflecting metabole acidss and increased ammonia reflecting hyperammonentia which may be associated with encephalopathy are described (see Warnings and Precautions (5.4 and 5.10)). However, the clinical significance of these other various abnormabiles in other clinical laboratory analytes described here has not been clearly established.

Epilepsy

Controlled trials of adjunctive topiramate treatment of adults for partial onset seizures showed an increased incidence of markedly decreased serum phosphorus (6% topiramate, 2% placebo), markedly increased serum alkaline phosphatase (3% topiramate, 1% placebo), and decreased serum potassium (0.4 % topiramate, 0.1 % placebo).

Changes in several clinical laboratory analytes (i.e., increased creatinine, BUN, alkaline phosphatase, total protein, total eosinophil count, and decreased potassium) have been observed in a clinical investigational program in very young (<2 years) pediatric patients who were treated with adjunctive topiramate for partial onset seizures [see Use in Specific Populations (8.4)].</p>

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

Acute Myopia and Secondary Angle Closure [see Warnings and Precautions (5.1)]

- Visual Field Defects [see Warnings and Precautions (5.2)] Oligohidrosis and Hyperthermia [see Warnings and Precautions (5.3)] Metabolic Acidosis [see Warnings and Precautions (5.4)]
- Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)] Cognitive/Neuropsychiatric Adverse Reactions [see Warnings and Precautions
- (5.6)] Fetal Toxicity [see Warnings and Precautions (5.7) and Use in Specific
- ations (8.1)] Withdrawal of Antiepileptic Drugs (AEDs) [see Warnings and Precautions (5.8)]
- Sudden Unexplained Death in Epilepsy (SUDEP) [see Warnings and Precautions (5.9)1
- Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use) [see Warnings and Precautions (5.10)] Kidney Stones [see Warnings and Precautions (5.11)]
- Hypothermia with Concomitant Valproic Acid (VPA) Use [see Warnings and ions (5.12)]

Precautio Paresthesia [see Warnings and Precautions (5.13)]

The data described in the following sections were obtained using topiramate tablets 6.1 Clinical Trial Experience

Monotherapy Epilepsy

Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidence or adverse reactions in the clinical trials of another drug, and may not reflect the incidence of adverse reactions observed in practice.

Increased Risk for Bleeding

Topiramate tablets treatment is associated with an increased risk for bleeding. In a pooled

poties analysis of placebo-controlled studies of approved and unapproved indications, bleeding was more frequently reported as an adverse event for topiramate tablets than for placebo (4.5% versus 3.0% in adult patients, and 4.4% versus 2.3% in pediatric patients). In this analysis, the incidence of serious bleeding events for topiramate tablets and placebo was 0.3% versus 0.2% for adult patients, and 0.4% versus 0% for pediatric patients.

Adverse bleeding reactions reported with topiramate tablets ranged from mild epistaxis, -vurse se usesung reactions reported with topiramate tablets ranged from mild epistaxis, ecclymosis, and increased menetrulai bleeding to life-threatenting hemorrhages. In patients with serious bleeding events, conditions that hicreased the risk for bleeding were often present, a patients were often taking drugs that cause thrombocytopenia (other antisplicit) or affect pletekt function or cogulation (e.g., asprin, nonsteroidal anti-infimmatory drugs, selective serotonin reuptake inhibitors, or warfarin or other anticogulants).

Monotherapy Epilepsy

Adults ≥16 Years

The adverse reactions in the controlled trial that occurred most commonly in adults in the 400 mg/day topiramate group and at a rate higher (a 5 %) than in the 50 mg/day group were: presentesia, weight decrease, anorexia, somnolence, and difficulty with memory (see Table 5).

Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. The most common (a 2% more frequent than bw-dose 50 mg/day topiramate) adverse reactions causing discontinuation in this trial were difficulty with memory, fatgue, asthenia, isnomina, sommolence, and paresthesia. Pediatric Patients 6 to <16 Years of Age

Pediatric padents 5 to <1b feas of Age The adverse reactions in the controlled trial that occurred most commonly in pediatric patients in the 400 mg/day topiramate tablets group and at a rate higher (\geq 5%) than in the 50 mg/day group were fever, weight decrease, mood problems, cognitive problems, infection, flushing, and paresthesia (see Table 5). Table 5 aks o presents the incidence of adverse reactions occurring in at least 2% of adult and pediatric patients trated with 400 mg/day topiramate tablets and occurring with greater incidence than 50 mg/day topiramate tablets.

top aniact coulds. Approximate 144% of the 77 pediatric patients in the 400 mg/day group who received topiramate tablets as monotherapy in the controlled chincal trial discontinued therapy due to adverse reactions. The most common (\geq 2% more frequent than low-does 50 mg/day topiramate) adverse reactions resulting in discontinuation in this trial were difficulty with concentration/statenton, fever, fluxion, and confluxion.

Table 5: Incidence of Treatment-Emergent Adverse Reactions in Monotherapy Epilepsy Where the Rate Was at Least 2% in Any Topiramate Tablets Group and the Rate in the 400 mg/day Topiramate Tablets Group Was Greater Than the Rate in the 50 mg/day Topiramate Tablets Group for Adults (216 Years) and Pediatric (6 to <16 Years) Patients in Study TOPMAX-EMM-106

	Age Group				
	Pediatric (6 to <16 Years)		Ad (Age ≥1	ult 6 Years)	
	Topiramate	Tablets Dail	y Dosage Gr	oup (mg/day	
	50	400	50	400	
Body System	(N=74)	(N=77)	(N=160)	(N=159)	
Adverse Reaction	%*	%*	%*	%*	
Body as a Whole - General Disorder	r s 0	3	4	6	
Asthenia Chest pain	0	3	4	2	
Fever	1	12	1	2	
Leg pain	1	12	2	3	
Central & Peripheral Nervous Syste	m Disorders		-	5	
Ataxia	in Disorders		3	4	
Dizziness			13	14	
Hypertonia			0	3	
Hypoesthesia			4	5	
Muscle contractions involuntary	0	3			
Paresthesia	3	12	21	40	
Vertigo	0	3			
Gastro-Intestinal System Disorders					
Constipation			1	4	
Diarrhea	8	9			
Gastritis			0	3	
Gastroesophageal reflux	_		1	2	
Dry mouth			1	3	
Liver and Biliary System Disorders					
Gamma-GT increased			1	3	
Metabolic and Nutritional Disorders					
Weight decrease	7	17	6	17	
Platelet, Bleeding & Clotting Disord	ers				
Epistaxis	0	4			
Psychiatric Disorders					
Anorexia			4	14	
Anxiety	-		4	6	
Cognitive problems	1	6	1	4	
Confusion	0	3			
Depression	0	3	7	9	
Difficulty with concentration/attention	,		7	8	
Difficulty with memory	1	3	6	9	
Insomnia			0	3	
Libido decreased Mood problems	1	8	2	5	
	0	3	2	5	
Personality disorder(behavior problems) Psychomotor slowing	0	3	3	5	
Somnolence			10	15	
Red Blood Cell Disorders			10	15	
Anemia	1	3		T	
Reproductive Disorders, Female [†]	1	3			
Intermenstrual Bleeding	0	3		T	
Vaginal Hemorrhage	U	2	0	3	
Resistance Mechanism Disorders	1	1	U	3	
Infection	3	8	2	3	
Infection viral	3	6	6	8	
Respiratory System Disorders		. v	ÿ		
Bronchitis	1	5	3	4	
Dyspnea	-		1	2	
Rhinitis	5	6	2	4	
Sinusitis	1	4	-	1	
Upper respiratory tract infection	16	18			
Skin and Appendages Disorders					
Acne			2	3	
Alopecia	1	4	3	4	
Pruritus			1	4	
Rash	3	4	1	4	
Special Senses Other, Disorders					
Taste perversion			3	5	
Urinary System Disorders					
Cystitis			1	3	
Dysuria			0	2	
Micturition frequency	0	3	0	2	
Renal calculus			0	3	
Urinary incontinence	1	3			
Urinary tract infection			1	2	
Vascular (Extracardiac) Disorders					
Flushing	0	5		1	
*Percentages calculated with the numbe	r of subjects i	n each group	as denominate		

L = J = 0 5 Tercentage cakulated with the number of subjects in each group as denominator Th with Female Reproductive Disorders - Incidence cakulated relative to the number of females; Pediatric TPM 50 mg n=40; Pediatric TPM 400 mg n=33; Aduit TPM 50 mg n=84; TPM 400 mg n=80

Adjunctive Therapy Epilepsy

Adjunctive Inerapy Epilepsy The most commonly observed adverse reactions associated with the use of topiramate tablets at dosages of 200 to 400 mg/day (recommended dose range) in controlled trials in adults with partial insert seizures, primary generalized tonic-choice seizures, or Lennox-Gastaut syndrome, that were seen at an incidence higher (2 5%) than in the placebo group were : somolence, weight decrease, anorexia, dizcines, atavia, speech disorders and related speech problems, language problems, psychomotor slowing, confusion, ahonormal vision, diffeculty with memory, paresthesia (ablopia, nervousness, and asthenia (see Table 6). Dose-related adverse reactions at dosages of 200 to 1,000

mg/day are shown in Table 8.

The most commonly observed adverse reactions associated with the use of topiramate tablets at dosages of 5 to 9 mg/kg/day in controlled trials in pediatric patients with partial onset seizures, primary generalized tonix-clonic seizures, or Lennox-Gastaut syndrome, that were seen at an incidence higher (± 5%) than in the placebo group were : fatigue, somnolence, anorexia, nervousness, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease (see Table 9). Table 9 also presents the incidence of adverse reactions occurring in at least 1% of pediatric patients treated with topiramate tablets and occurring with greater incidence than placebo.

treated with topiramate tablets and occurring with greater incidence than piacetable. In controlled clinical trials in adults, 11% of patients receiving topiramate tablets 200 to 400 mg/day as adjunctive therapy discontinued due to adverse reactions. This rate appeared to increase at dosages above 400 mg/day. Adverse reactions associated with discontinuity therapy included somolence, dazieness, anxiety, difficulty with concentration or attention, fatigue, and paresthesia and increased at dosages above 40 mg/day as to 8 mg/day in controlled clinical trials discontinued tablets adjunctive therapy at 5 to 8 mg/dg/day in controlled clinical trials discontinued due to adverse reactions.

reactions. Approximately 28% of the 1757 adults with epilepsy who received topiramate tablets at dosages of 200 to 1,600 mg/day in clinical studies discontinued treatment because of adverse reactions; an individual patient could have reported more than one adverse reaction. These adverse reactions were psychomotor slowing (4.0%), difficulty with memory (3.2%), fattyue (3.2%), contrusion (3.1%), somolecne (3.2%), difficulty with concentration/attention (2.9%), anorexia (2.7%), depression (2.6%), disziness (2.5%), weight decrease (2.5%), nervousness (2.3%), attax (3.1%), and paresthesia (2.0%). dosages up to 30 mg/kg/day discontinued due to adverse reactions. Adverse reactions associated with discontinuing therapy included aggravated convulsions (2.3%), difficulty with concentration/attention (1.6%), language problems (1.3%), personality (1.3%), and somolence (1.3%).

Incidence in Epilepsy Controlled Clinical Trials - Adjunctive Therapy - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Lennox-Gastaut Syndrome

Gastaut syndrome Table 6 lists treatment-emergent adverse reactions that occurred in at least 1% of adults treated with 200 to 400 mg/day topiramate tablets in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse reactions during the first eight weeks of these trials no longer experienced them by their last visit. Table 9 lists treatmentemergent adverse reactions that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/dkg topiramate tablets in controlled trials that were numerically more common than in patients treated with placebo.

common man in patients treated with piacebo. The prescriber should be aware that these data were obtained when topiramate tablets was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevaling during clinical studies. Similarly, the clied frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. In back these frequencies, however, does provide the prescribing physician with a back the set of the population studied.

Other Adverse Reactions Observed During Double-Blind Epllepsy Adjunctive Therapy Trials

Other adverse reactions that occurred in more than 1% of adults treated with 200 to 400 mg of topiramate in placebo-controlled epilepsy trials but with equal or greater frequency in the placebo group were headachet, injury, anxiety, rash, pain, convulsions aggravated, coughing, fever, diarrhea, vomiting, muscle weakness, insomnia, personality disorder, dysmeorrhea, upper respiratory tract infection, and eye pain.

Table 6: Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Adults⁻¹ (Where Incidence Was >1% in Any Topiramate Tablets Group and Greater Than the Rate in Placebo-Treated Patients

Body System/	Placebo	200-400	osage (mg/day) 600-1,000
Adverse Reaction [‡]	(N=291)	(N=183)	(N=414)
Body as a Whole - General Disorders	13	15	30
Fatigue Asthenia	13	6	30
Back pain	4	5	3
Chest pain	3	4	2
Influenza-like symptoms	2	3	4
Leg pain	2	2	4
Hot flushes	1	2	1
Allergy	1	2	3
Edema	1	2	1
Body odor	0	1	0
Rigors	0	1	<1
Central & Peripheral Nervous System			
Dizziness	15	25	32
Ataxia	2	16	14
Speech disorders/Related speech problems Paresthesia	4	13	11
Nystagmus	7	10	19
Tremor	6	9	9
Language problems	1	6	10
Coordination abnormal	2	4	4
Hypoesthesia	ĩ	2	1
Gait abnormal	1	3	2
Muscle contractions involuntary	1	2	2
Stupor	0	2	1
Vertigo	1	1	2
Gastro-Intestinal System Disorders			
Nausea	8	10	12
Dyspepsia	6	7	6
Abdominal pain	4	6	7
Constipation	2	4	3
Gastroenteritis	1	2	1
Dry mouth	1	2	4
Gingivitis	<1	1	1
GI disorder	<1	1	0
Hearing and Vestibular Disorders			
Hearing decreased	1	2	1
Metabolic and Nutritional Disorders Weight decrease	3	9	13
Muscle-Skeletal System Disorders	2	9	15
Myalgia	1	2	2
Skeletal pain	ō	1	0
Platelet, Bleeding, & Clotting Disorder	5		
Epistaxis	1	2	1
Psychiatric Disorders			
Somnolence	12	29	28
Nervousness	6	16	19
Psychomotor slowing	2	13	21
Difficulty with memory	3	12	14
Anorexia	4	10	12
Confusion	5	11	14
Depression	2		
Difficulty with concentration/attention	2	6 4	14 9
Mood problems Agitation	2	4	3
Aggressive reaction	2	3	3
Emotional lability	1	3	3
Cognitive problems	1	3	3
Libido decreased	1	2	<1
Apathy	î	1	3
Depersonalization	1	1	2
Reproductive Disorders, Female			_
Breast pain	2	4	0
Amenorrhea	1	2	2
Menorrhagia	0	2	1
Menstrual disorder	1	2	1
Reproductive Disorders, Male			
Prostatic disorder	<1	2	0
Resistance Mechanism Disorders			
Infection	1	2	1
Infection viral	1	2	<1
Moniliasis	<1	1	0
Respiratory System Disorders	6		
Pharyngitis	2	6	3
Rhinitis	6	7	6
Sinusitis		5	
Dyspnea Skin and Appendages Disorders	1	1	2
Skin and Appendages Disorders Skin disorder	<1	2	1
Skin disorder Sweating increased	<1 <1	2	1 <1
oweaung increased	<1	-	<1

<1	1	<1
0	2	4
1	2	<1
1	2	3
1	1	2
<1	2	1
0	1	<1
2	13	10
5	10	10
1	2	1
	0 1 1 1 <1 0 2	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

Patients in these add-on/ adjunctive trials were receiving 1 to 2 concomtant anticipleptic drugs in addition to topiramate tablets or placebox Tvalues represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction during the study and can be included in more than one adverse reaction during the study and can be included in more than one adverse reaction during the study and can be included in more than one adverse reaction during the study and the fadverse reactions reported by at least 1% of patients in the topiramate tablets 200-400 mg/day group and more common than in the placebo group are listed in this table.

Incidence in Study 119 - Add-On Therapy- Adults with Partial Onset Seizures

Study 110 was a randomized, double-bind, add-on/adjunctive, placebo-controled, parakle group study with 3 treatment arms: 1) placebo; 2) topiramate tablets 200 mg/day with a 25 mg/day starting dose, increased by 25 mg/day each week for 8 weeks until the 200 mg/day maintenance dose was reached; and 3) topiramate tablets 200 mg/day with a control of the starting of the starting

Concompant can be available with on window anoune concompant anteppent unique. The most commonly observed adverse reactions associated with the use of topramate tablets that were seen at an incidence higher (s 5%) than in the placebo group were : paresthesia, nervousness, schnolence, difficulty with concentration/attention, and faitigue (see Table 7). Because these topramate tablets treatment difference incidence (Topramate Tablets %). Placebox %) of many adverse reactions reported in this study we directly compared with data obtained in other studies.

Table 7: Incidence of Treatment-Emergent Adverse Reactions in Study 119*,[†] Where Incidence Was ≥ 2% in the Topiramate Tablets Group and Greater Than the Rate in Placebo-Treated Patients

		Topiramate Tablets Dosage (mg/day)
Body System/	Placebo	200
Adverse Reaction [‡]	(N=92)	(N=171)
Body as a Whole-General Disorde	rs	
Fatique	4	9
Chest pain	1	2
Cardiovascular Disorders, Genera	I	*
Hypertension	0	2
Central & Peripheral Nervous Sys	tem Disorders	5
Paresthesia	2	9
Dizziness	4	7
Tremor	2	3
Hypoesthesia	0	2
Leg cramps	0	2
Language problems	0	2
Gastro-Intestinal System Disorde	rs	
Abdominal pain	3	5
Constipation	0	4
Diarrhea	1	2
Dyspepsia	0	2
Dry mouth	0	2
Hearing and Vestibular Disorders		
Tinnitus	0	2
Metabolic and Nutritional Disorde	rs	
Weight decrease	4	8
Psychiatric Disorders		
Somnolence	9	15
Anorexia	7	9
Nervousness	2	9
Difficulty with concentration/attention	0	5
Insomnia	3	4
Difficulty with memory	1	2
Aggressive reaction	0	2
Respiratory System Disorders		
Rhinitis	0	4
Urinary System Disorders	-	
Cvstitis	0	2
Vision Disorders	-	
Diplopia	0	2
Vision abnormal	0	2
*Patients in these add-on/adjunctive tr	ials were receivi	ing 1 to 2 concomitant antienilentic

[•]Patients in these add-on/adjunctive trials were receiving 1 to 2 concomitant anticpleptic drugs in addition to top/arameter tables or placecebo. [•]Nalues represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction drugs the study and can be included in more than one adverse reaction category. [•]Fadverse reactions reported by at least 25% of patients in the top/aramate tablets 200 mg/day group and more common than in the placebo group are listed in this table.

Table 8: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, Add-On Trials in Adults With Partial Onset Seizures*

		Topiramate Tablets Dosage (mg/d		
	Placebo	200	400	600 - 1,000
Adverse Reaction	(N = 216)	(N = 45)	(N = 68)	(N = 414)
Fatigue	13	11	12	30
Nervousness	7	13	18	19
Difficulty with concentration/attention	1	7	9	14
Confusion	4	9	10	14
Depression	6	9	7	13
Anorexia	4	4	6	12
Language problems	<1	2	9	10
Anxiety	6	2	3	10
Mood problems	2	0	6	9
Weight decrease	3	4	9	13
*Dose-response studies were not conducted for other adult indications or for pediatric indications.				

Table 9: Incidence (%) of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Pediatric Patients (Ages 2 - 16 Years)¹ (Reactions That Occurred in at Least 1% of Topiramate Tablets-Treated Patients and Occurred More Frequently in Topiramate Tablets-Treated Than Placebo-Treated Patients)

Body System/	Placebo	Topiramate
Adverse Reaction	(N=101)	(N=98)
Body as a Whole - General Disorders	(11-101)	(11=50)
Fatique	5	16
Injury	13	14
Allergic reaction	1	2
Back pain	0	1
Pallor	0	1
Cardiovascular Disorders, General		1
Hypertension	0	1
Central & Peripheral Nervous System	Disorders	
Gait abnormal	5	8
Ataxia	2	6
Hyperkinesia	4	5
Dizziness	2	4
Speech disorders/Related speech problems	2	4
Hyporeflexia	0	2
Convulsions grand mal	0	1
Fecal incontinence	0	1
Paresthesia	0	1
Gastro-Intestinal System Disorders		
Nausea	5	6
Saliva increased	4	6
Constipation	4	5
Gastroenteritis	2	3
Dysphagia	0	1
Flatulence	0	1
Gastroesophageal reflux	0	1
Glossitis	0	1
Gum hyperplasia	0	1
Heart Rate and Rhythm Disorders		

Bradycardia	0	1
Metabolic and Nutritional Disorders		
Weight decrease	1	9
Thirst	1	2
Hypoglycemia	0	1
Weight increase	0	1
Platelet, Bleeding, & Clotting Disorders		
Purpura	4	8
Epistaxis	1	4
Hematoma	0	1
Prothrombin increased	0	1
Thrombocytopenia	0	1
Psychiatric Disorders		
Somnolence	16	26
Anorexia	15	24
Nervousness	7	14
Personality disorder (behavior problems)	9	11
Difficulty with concentration/attention	2	10
Aggressive reaction	4	9
Insomnia	7	8
Difficulty with memory	0	5
Confusion	3	4
Psychomotor slowing	2	3
Appetite increased	0	1
Neurosis	0	1
Reproductive Disorders, Female		•
Leukorrhea	0	2
Resistance Mechanism Disorders		
Infection viral	3	7
Respiratory System Disorders		
Pneumonia	1	5
Respiratory disorder	0	1
Skin and Appendages Disorders		
Skin disorder	2	3
Alopecia	1	2
Dermatitis	0	2
Hypertrichosis	1	2
Rash erythematous	0	2
Eczema	0	1
Seborrhea	0	1
Skin discoloration	0	1
Urinary System Disorders		
Urinary incontinence	2	4
Nocturia	0	1
Vision Disorders		
Eye abnormality	1	2
Vision abnormal	1	2
Diplopia	0	1
Lacrimation abnormal	0	1
Myopia	0	1
White Cell and RES Disorders		
	0	

Leukopenia 0 2
*Patients in these add-on/adjunctive trials were receiving 1 to 2 concomitant antiepileptic

radies in these oursynapping the transmission of the constraint an uppen drugs in addition to topiramate tablets or placed. Tvalues represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

Other Adverse Reactions Observed During All Epilepsy Clinical Trials

Other Adverse Reactions Observed During All Epilepsy Clinical Trials Topiramate tables has been administered to 2246 adults and 427 pediatric patients with epilepsy during all clinical studies, only some of which were placebo-controlled. During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of reactions were grouped into a smaller number of standardized categories using modified WH0ART dictionary terminology. The frequencies presented represent the proportion of patients who experimented a reaction of the type clead on at least one occasion while receiving inversions tables or text, those too general to be informable, and those next yields and associated with the use of the drug.

Reactions are classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent occurring in at least 1/100 patients; infrequent occurring in 1/100 to 1/1000 patients; rare occurring in fewer than 1/1000 patients.

Autonomic Nervous System Disorders: Infrequent: vasodilation

Body as a Whole: Frequent: syncope. Infrequent: abdomen enlarged. Rare: alcohol intolerance.

Cardiovascular Disorders, General: Infrequent: hypotension, postural hypotension, angina pectoris. Central & Peripheral Nervous System Disorders: Infrequent: neuropathy, apraxia, hyperesthesia, dyskinesia, dysphonia, scotoma, ptosis, dystonia, visual field defect, encephalopathy, EEG abnormal. Rare: upper motor neuron lesion, cerebellar syndri tongue paralysis.

-, rome Gastrointestinal System Disorders: Infrequent: hemorrhoids, stomatitis, melena, gastritis, esophagitis. Rare: tongue edema.

Heart Rate and Rhythm Disorders: Infrequent: AV block.

Liver and Biliary System Disorders: Infrequent: SGPT increased, SGOT increased. Metabolic and Nutritional Disorders: Infrequent: dehydration, hypocalcemia, hyperlipemia, hyperglycemia, xerophthalmia, diabetes mellitus. Rare: hypernatremia, hyponatremia, hypocholesterolemia, creatinine increased.

Musculoskeletal System Disorders: Frequent: arthralgia. Infrequent: arthrosis. Neoplasms: Infrequent: thrombocythemia. Rare: polycythemia.

Platelet, Bleeding, and Clotting Disorders: Infrequent: gingival bleeding, pulmonary embolism.

Psychiatric Disorders: Frequent: impotence, hallucination, psychosis, suicide attempt. Infrequent: euphoria, paranoid reaction, delusion, paranoia, delirium, abnormal dreaming. Rare: libido increased, manic reaction.

Red Blood Cell Disorders: Frequent: anemia. Rare: marrow depression, pancytopenia. Reproductive Disorders, Male: Infrequent: ejaculation disorder, breast discharge. Skin and Appendages Disorders: Infrequent: urticaria, photosensitivity reaction, abnormal hair texture. Rare: chloasma.

Special Senses Other, Disorders: Infrequent: taste loss, parosmia.

Urinary System Disorders: Infrequent: urinary retention, face edema, renal pain, albuminuria, polyuria, oliguria.

Vascular (Extracardiac) Disorders: Infrequent: flushing, deep vein thrombosis, phlebitis. Rare: vasospasm

Vision Disorders: Frequent: conjunctivitis. Infrequent: abnormal accommodation, photophobia, strabismus. Rare: mydriasis, iritis.

White Cell and Reticuloendothelial System Disorders: Infrequent: lymphadenopathy, eosinophilia, lymphopenia, granulocytopenia. Rare: lymphocytosis.

6.2 Postmarketing and Other Experience

In addition to the adverse experiences reported during clinical testing of topiramate tablets, the following adverse experiences have been reported worldwide in patients receiving topiramate tablets post-approval.

These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bullous skin reactions (including explorem) and therme. Stevens-Johnson syndrome, toxic epidermal necrolysis), hepatic failure (including fatalities), hepatitis, maculopathy, pancreatilis, and perphilipus:

7 DRUG INTERACTIONS

/ DRUG INI LEAL TIONS In vitro's studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2Q9, CYP2D6, CYP2E1, and CYP3A4/S isozymes. In vitro's studies indrate that topiramate is a mill inhibitor of CYP219 and a mill inducer of CYP3A4. Drug interactions with some antiepilepit drugs, CNS depressants and oral contraceptives are described here. For other drug interactions, please refer to *Clinical Pharmacology* (12.3).

7.1 Antiepileptic Drugs

A interpreter of upp Potential Interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epikepsy. Concomitant administration of phenytoin or carbamazepine with topiramate devices. Concentrations of Topiramate by 48% and 40%, respectively when compared to topiramate given alone (see Cinical Pharmacology (12.3).)

Concomitant administration of valproic acid and topiramate tablets has been associated with hyperammonemia with and without encephalopathy. Concomtant administration of topiramate tablets with valproic acid has also been associated with hypothermia (with

and without hyperammonemia) in patients who have tolerated either drug alone. It may be prudent to examine blood ammonia levels in patients in whom the onset of hypothermia has been reported [see Warnings and Precautions (5.10), (5.12) or Clinical Pharmacology (12.3)].

7.2 CNS Depressants

7.3 Oral Contraceptives

7.3 Oral Contraceptives
Exposure to tehniyl estraidiol was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when topiramate tablets was given as adjunctive therapy in patients taking vaporic acid. However, norethindrone exposure was not significantly affected. In another pharmacokinetic interaction study in healthy volunteers with a concombantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) pixs 35 mcg ethnyl estradiol (EE), topiramate tablets, given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in men exposure (AUC) to other component of the oral contraceptive. The possibility of decreased in patients taking combination oral contraceptive products with topiramate tablets. Patients taking estimate-nontanion contraceptive products with report and tables. Patients taking estimate-nontanion contraceptive products with report any tables. Patients padents taking estrogen-containing contraceptive products with opinaniae tables, radents taking estrogen-containing contraceptive should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see *Clinical Pharmacology (12.3)*].

7.4 Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].

In patients, likhum levels were unaffected during treatment with topiramate at doses of 200 mg/day, however, there was an observed increase in systemic exposure of likhum (27% for Cmax and 25% for AUC) following topiramate doses of up to 600 mg/day. Likhum levels should be monitored when co-administered with high-dose topiramate tablets/see Ciffical Pharmacology (2.2)).

7.6 Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide, or dichlorphenamide) may increase anyon as eminuted (e.g., Zohaaninae, acteacoaninae, on ochino principae) and the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, if topiramate tablets is given concomitantly with another carbonic anyolrase inhibitor, the patient should be monitored for the appearance or worsening metabolic acidosis (see Clinical Pharmacology (12.3)).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D [see Warnings and Precautions 5.7]

<u>PrenancyLatedory Lisee Warmages and Precautions 5.71</u> Topiramate tablets can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate *in utero* have an increased risk for cleft it pandor cleft clefts. When multiple species of pregnant animals received topiramate at clinically relevant doses, structural maformations, including cranoficial defects, and reduced felat weights occurred in offspring. Topiramets tablets should be used during pregnancy only if the potential benefit outweights the potential is. If this drug is used during pregnancy, or if the benefit outweights the potential topic is used during pregnancy or the be-benefit outweights the potential topic is the distribution of the potential hazard to a fetus [see Use in Specific Populations (8-9)].

Pregnancy Registry

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enrol, pa-can cal the toll-free number 1-888-233-2334. Information about the North Americ Drug Pregnancy Registry can be found at http://www.massgeneral.org/aed/. can cali un Drug Preg

Human Data

Tuman Losa Data from the NAAED Pregnancy Registry (425 prospective topiramate monotherapy-exposed pregnancies) indicate an increased risk of oral clefts in infants exposed during the first trimester of pregnancy. The prevalence of oral clefts among topiramate-exposed infants was 1.2% compared to a prevalence of 0.39% for infants exposed to a reference AED. In infants of mothers without epilepsy or tratement with other AEDs. The prevalence was 0.12%, For comparison, the Centers for Disease Control and Prevention (CDC) reviewed available data on oral clefts in the United States and found a similar background rate of 0.17%.

background rate of 0.1%. The relative risk of oral ciefts in topiramate-exposed pregnancies in the NAAED Pregnancy Registry was 9.6 (95% Confidence Interval (CI) 4.0 – 23.0) as compared to the risk in a background population of untreated women. The UK Eplepsy and Pregnancy Registry exported a similary in creased prevalence of oral clefts of 3.2%s among infants exposed to topiramate monotherapy. The observed rate of oral cleft was 16 times higher than the background rate in the UK, which is approximately 0.2%. Topiramate tablets treatment can cause metabolic acidosis fase not been studied in pregnancy, however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus' ability to tolarate labor. Pregnant tablet should be monkored for metabolic acidosis and treated as in the nonpregnant state (see Warnings and *Precautions (5.4)*). Newforces of the acid oxygenation, and fetal death, and may affect the relative should be been studied with optiramate tablets should be monkored for metabolic acidosis because of transfer of topiramate tablets should be monkored for metabolic acidosis because of transfer of topiramate tablets should be possible occurrence of transient metabolic acidosis following birth.

Animal Data

Topiranate has demonstrated selective developmental toxicity, including teratogenicity, in multiple animal species at clinically relevant doses. When oral doses of 20, 100, or 500 mugfix ever a doministered to programit mice during the period of organogenesis, the incidence of fetal matiomations (primarily cranifical defects) was increased at all 400 mg/day on a mg/m²basis. Fetal body weights and skeletal software reduced at 500 mg/kg in conjunction with decreased maternal body weight gain.

as Job mgkg in recipion man because material box median signal. In rat studies (oral does of 20, 100, and 500 mg/kg or 0.2, 2.5, 30, and 400 mg/kg), the frequency of lmb maformations (ectrodacty), micromela, and amela) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m2basis) or greater during the organogenesis period of pregnancy. Embryotoxicity (reduced feta body weights, increased and increased increased microme of structural variations) was observed at doese as bw as 20 mg/kg (10.5 times the RHD on a mg/m2basis). Clinical signs of material toxicity were seen at 400 mg/kg and above, and material body weight gain was reduced during treatment with 100 mg/kg or greater

In rabbit studies (20, 60, and 140 rod mgkg of 1924ef) mgkg or greater) mgkg or greater) mgkg or rabbit studies (20, 60, and 140 mgkg or 10, 35, and 120 mgkg or 20, 35, and 120 mgkg or 20, 35, and 120 mgkg or 20, and 25, a

mortany) was seen at 25 mg/kg and above. When female rats were treated during the latter part of gestation and throughout lactation (0.2, 4, 20, and 100 mg/kg), and 200 mg/kg), offspring exhibited decreased vability and delayed physical development at 200 mg/kg (5 times the RHD on a mg/m² basis) and reductions in preand/or postweaning body weight gain at 2 mg/kg (0.05 times the RHD on a mg/m² basis) and above. Maternai toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg or greater.

wegyns gant, central sygna) was evident at LUD mg/kg or greater. In a rat embryoffetal development study with a postnatal component (0.2, 2.5, 30, or 400 mg/kg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/kg (10 times the RHD on a mg/m² basis) and persistent reductions in body weight gain at 30 mg/kg (1 times the RHD on a mg/m² basis) and hgher.

8.2 Labor and Delivery

Although the effect of topiramate tablets on labor and delivery in humans has not been established, the development of topiramate-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus' ability to tolerate labor [see Use in Specific Populations (8.1)].

8.3 Nursing Mothers

Limited data on 5 breastfeeding infants exposed to topiramate showed infant plasma topiramate levels equal to 10-20% of the maternal plasma level. The effects of this exposure on infants are unknown. Caution should be exercised when administered to a nursing woman.

8.4 Pediatric Use

Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers (1 to 24 months

Safety and effectiveness in patients below the age of 2 years have not been established for the adjunctive therapy treatment of partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. In a single randomized, double-blind, placebo-controlled investigational trial, the efficacy, safety, and tolerability of topiramate oral iquid and sprinkle formulations as an adjunct to concurrent antiepileptic drug therapy in infants 1 to 24 months of age with refractory partial onset setures were assessed. After 20 days of double-blind treatment,

topiramate (at fixed doses of 5, 15, and 25 mg/kg/day) did not demonstrate efficacy compared with placebo in controlling seizures.

In general, the adverse reaction profile in this population was similar to that of older pediatric patients, although results from the above controlled study and an open-la pediatric patients, athough results from the above controlled study and an open-label, long-terre actension study in these infants/foddiers (1 to 24 months odi) suggested some adverse reactions/toxicities (not previously observed in older pediatric patients and aduts: Le, growth/neght reardation, certain clinical aboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greate severity than had been recognized previously from studies in older pediatric patients or adults for various indications.

adults for various incl. adults. These very young pediatric patients appeared to experience an increased risk for infections (any topiramate dose 12%, placebo 0%) and of respiratory disorders (any topiramate dose 40%, placebo 10%). The following adverse reactions were observed in at least 3% of patients on topiramate and were 3% to 7% more frequent than in patient on placebo: viral infection, bronchis, planyngits, hinks, ottis media, upper respirator infection, cough, and bronchospasm. A generally similar profile was observed in older children (see Adverse Reactions; ferror Hyperink reference and valid.);

Linux-ref Jose Auverse Réaction's (Error! Hyperlink reference not Valid.)). Topiamate resulted ha in increased incidence of patients with hire-resed creatine (any topiamate doss 5%, placebo 0%), BUN (any topiamate dose 3%, placebo 0%), and protein (any topiamate dose 3%, placebo 0%), Man (any topiamate dose 3%, placebo 0%), decreased patassium (any topiamate dose 7%, placebo 0%). This increased frequency of ahormar Values was not doser created: Creatine was the only analyte showing a noteworthy increased incidence (topiamate 25 mg/kg/day 5%, placebo 0%) of a markedly abnormal increase (see Warnings and Precautions (5.16)). The significance of these findings is uncertain.

these runnings is uncertain. Topiramate treatment also produced a dose-related increase in the percentage of patients who had a shift from normal at baseline to high/increased (above the normal reference range) in total esolishopil count at the end of treatment. The incidence of these abnormal shifts was 6 % for placebo. 10% for 5 mg/kg/day, 9% for 15 mg/kg/day, 14% for 25 mg/kg/day, and 11% for any topiramate dose (*see Warnage and Precations* (*5*.100). There was a mean dose-related increase in akaline phosphatase. The significance of these findings a uncertain.

Topiramate produced a dose-related increased incidence of treatment-em hyperammonemia [see Warnings and Precautions (5.10)].

Treatment with topiramate for up to 1 year was associated with reductions in 2 SCORES for length, weight, and head circumference (see Warnings and Precautions (5.4) and Adverse Reactions (Error! Hyperlink reference not valid.)].

Advesse heat.com/s (Erlor) reprenent reference into vank.//. In oper-label, uncontrolled experience, increasing impairment of adaptive behavior was documented in behavioral testing over time in this population. There was a suggestion that this effect was dosc-related. However, because of the absence of an appropriate control group, it is not known if this decrement in function was treatment-related or refersts the patient's underlying disease (e.g., patients who received higher doses may have more severe underlying disease) [see Warnings and Precautions (5.6)].

In this open-label, uncontrolled study, the mortality was 37 deaths/1000 patient years. It is not possible to know whether this mortality rate is related to topiramate treatment, because the background mortality rate for a related to topiramate treatment, pediatric population (1-24 months) with partial epilepsy is not known.

Monotherapy Treatment in Partial Onset Epilepsy in Patients <2 Years Old Safety and effectiveness in patients below the age of 2 years have not been established for the monotherapy treatment of epilepsy.

Juvenile Animal Studies

When topiramate (30, 90, or 300 mg/kg/day) was administered orally to rats during the juvenile period of development (postnatal days 12 to 50), bone growth plate thickness was reduced in makes at the highest dose, which is approximately 58 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m²) maxir basis.

8.5 Geriatric Use

In clinical trials, 3% of patients were over 60. No age-related differences in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 55 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with imparied renal function (creating clearance rate < 70 mL/min/1.73 m²) due to reduced [see Clinical Pharmacology (12.3) and Dosage and Administration (2.5)].

8.6 Race and Gender Effect

Evaluation of effectiveness and safety in clinical trials has shown no race- or gender-related effects.

8.7 Renal Impairment

6.7 Kenta Impantient The clearance of topramate was reduced by 42% in moderately renally impaired (creatinne clearance 30 to 69 mL/min/1.73m²) and by 54% in severely renally impaired subjects (creatinne clearance >30 mL/min/1.73m²) compared to normal renal function subjects (creatinne clearance >70 mL/min/1.73m²). One-haft the usual starting and maintenance does is recommended in patients with moderate or severe renal impairment [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].

8.8 Patients Undergoing Hemodialysis

Topiranate is cleared by hemodalysis at a rate that is 4 to 6 times greater than in a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fail belw that required to maintain an anti-secure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate tablest. may be required.

The actual adjustment should take into account the duration of dialysis period, the clearance rate of the dialysis system being used, and the effective renal clearance topramate in the patient being dialyzed (see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]

8.9 Women of Childbearing Potential

8.9 Women of Childbearing Potential Data from pregnancy registrics indicate that infants exposed to topiramate tablets in data from pregnancy registrics indicate that infants exposed to topiramate tablets in different data and the second second second second second second the risks of topiramate tablets when prescribing this drug to women of childbearing potentia, particularly when topiramate tablets is considered for a condition not usually associated with pernament injury or death. Because of the risk of oral ciefts to the fetus, which occur in the first trinester of pregnancy before many women know they are pregnant, all women of childbearing potential should be apprised of the potential hazard to the fetus from exposure to topiramate tablets. If the decision is made to use topiramate tablets, women who are not planning a pregnancy should use effective contraception *Beo Drug Interactions (7.3)*. Women who are planning a pregnancy should be counseled regarding the relative risks and benefits of topiramate tablets use patients *fise Patient Counseling Information (Errort Hyperlink reference not valid.)*].

10 OVERDOSAGE

Overdoses of topiramate tablets have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, dipiopla, mentation impared, ethangy, abnormal coordination, stupport, hypotension, addominal pair, agtation, discriness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after poly-drug overdoses involving Topiramate. Topiramate overdose has resulted in severe metabolic acidosis [see Warnings and Precautions (5.4)].


A patient who ingested a dose between 96 and 110 g topiramate was admitted to a hospital with a coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days

In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate in *vitro*. Treament should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body

11 DESCRIPTION

Topiramate is a sulfamate-substituted monosaccharide. Topiramate tablets USP are available as 25mg, 50 mg and 100 mg circular tablets and 200 mg capsule shaped tablets for oral administration.

taxes to to an autimise auto. Topiramate USP is a white crystalline powder with a bitter taste. Topiramate USP is most soluble in akaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 90 to 10. Its freely soluble in a actone, choroform, dimethyslubickle, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate is a beignated chemically as 2,3-4,50-0-Sopropyldene-8-D-fructopyranose suffamate and has the following structural formula:



Each tablet, for oral administration, contains 25 mg, 50 mg, 100 mg and 200 mg topiramate and has the following hactive ingredients: hypromeliose, lactose monohydrate, magnesium stearate, microcrystillane cellulose, polyethylene glycol, polyeorbate 80, pregelatinized starch, sodium starch glycolate and tRanium dixxide. In addition, the 25 mg also contains FD&C Blue #2; the 50 mg and 100 mg also contain red iron oxide and yellow iron oxide; and the 200 mg also contains red iron oxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanisms by which topiramate exerts its anticonvulsant are unknown The precise mechanisms by which topiramate exerts its anticonvulsant are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate efficacy for epilepsy. Electrophysiological and blochemical evidence suggests that Topiramate, a pharmacological y relevant concentrations, blocks: voltage-dependent sodium channebs, augments the activity of the neurotransmitter gamma-minobutyrate a some subtypes of the GBAA-treceptor, analogicate the AMPA/kanate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly bozymes II and IV.

12.2 Pharmacodynamics

L2.2 Pharmacoognamics Topiramate has anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests. Topiramate is only weakly directive in blocking clonic seizures induced by the GABA, receptor antagonict, pentylemetetrazole. Topiramate is also effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SEB) and tonic and clonic seizures induced in rats by kinding of the amygdala or by global schemia.

12.3 Pharmacokinetics

Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose. The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution. The bioavailability of topiramate is not affected by food.

bioavailability of topiratinates in to altected by 1000. The pharmacohietics of topiramet are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination haf-life is 21 hours after single or multiple doses. Steady-state is thus reached in about 4 days in patients with normal renaf function. Topiramate is 15% to 41% bound to human plasma proteins over the bolod concentration range of 0.5 to 250 µg/mL. The fraction bound decreased as blood concentration increased.

Carbamazerine and phenytoin to not after the binding of topiramate. Sodium value at 500 ug/ml, (a concentration 5 to 10 times higher than considered therapeutic fr valueroate) decreased the protein binding of topiramate from 23% to 13%. Topiran does not influence the binding of sodium valproate. oate

Metabolism and Excretion

retreations in and Excretion Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Sk metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is evidence of renal tubular reabsorption of topiramate. In rats, given probenecid to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evaluated in humans. Overail, oral plasma clearance (CL/F) is approximately 20 to 30 mL/min in adults following oral administration.

Special Populations

Renal Impairment

The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m²) and by 54% in severely renally impaired subjects (creatinine clearance 30 mL/min/1.73m²) compared to normal renal function subjects (creatinine clearance > 30 mL/min/1.73m²). Since topiramate is presumed to undergo significant tubular readom to the subject of the severe increating the generated to all stuations of renal impairment. It is conceivable that some forms of reading the severe severe the severe severe the severe increase and the severe severe severe severe the severe severe severe severe reading the severe severe severe severe severe severe severe to the severe severe severe severe severe severe severe however, use of one-half the usual starting and maintenance dose is recommended in pairents with moderate or severe renal impairment. Sev Dnsae and Administration (2.4) patients with moderate or severe renal impairment [see Dosage and Administration (2.4) and (2.5) and Warnings and Precautions (5.14)]. Hemodialysis

Topiramate is cleared by hemodialysis. Using a high-efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyzer at 400 mL/min. This high clearance (compared to 20 to 30 mL/min totaloral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodalysis treatment period. Therefore, a supplemental dose may be required [see Dosage and Administration (2.6)].

Hepatic Impairment

In hepatically impaired subjects, the clearance of topiramate may be decreased; the mechanism underlying the decrease is not well understood [see Dosage and Administration (2.7)].

Age, Gender, and Race

Age, Gender, and Race The pharmacokinetics of topiramata in elderly subjects (65 to 85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function (creatinine clearance [>20%]) compared to young adults. Following a single achieved at agrowthmately 1 to 2 hours. Federating the primary renal elimitation of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%, respectively, in elderly subjects. compared to young adults. Similarly, topiramate half-life was longer (13%) in the elderly. Reduced topiramate clearance resulted in slightly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young adults. Topiramate clearance is decreased in the elderly only to the extent that renal function is reduced. As recommended for al platients, dosige adjustment may be indicated in the elderly hatient when impaired renal function in the elderly patient (see Dosage and Administration (2.4) and Warnings and Precautions (5.14)]. Clearance of Topiramate in clearance is a clearance in clearance rate = 270 mL/min(1.73 m²) is evident the was not affected by cender or care.

Clearance of Topiramate in adults was not affected by gender or race.

Pediatric Pharmacokinetics

reuse trainmacuknetics
Pharmacokinetics of topiramate were evaluated in patients aged 2 to <16 years. Patients received either no or a combination of other antiepileptic drugs. A population pharmacokinetic model was developed on the basis of pharmacokinetic data from relevant topiramate clinical studies. This dataset contained data from 1217 subjects including 258 pediatric patients aged 2 to <16 years (95 pediatric patients <10 years of age).</p>

Age: Pediatric patients on adjunctive treatment exhibited a higher oral clearance (*L/h*) of topiramate compared to patients on monotherapy, presumably because of increased clearance from concomitant enzyme-inducing antipelipetic drugs, in comparison, topiramate clearance per kg is greater in pediatric patients than in aduts and in young pediatric patients (down to 2 years) than in older pediatric patients. Consequently, the plasma drug concentration for the same mg/kg/day dose would be lower in pediatric patienter to adults and also in younger pediatric patients compared to older pediatric patients. Clearance was independent of dose.

As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.

Drug-Drug Interactions

Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 13.

In Table 13, the second column (see a summing etc) III (but 13, In Table 13, the second column (second) describes what happens to the concentration of the AED listed in the first column when topramate is added. The third column (topramate concentration) describes how the co-administration of a drug listed in the first column modifies the concentration of topramate in experimental settings when topramate was own ahone.

Table 13: Summary of AED Interactions with Topiramate Tablets
 AED Co-administered
 AED Concentration
 Topiramate Concentration

 Phenytoin
 NC or 25% increase*
 48% decrease

NC 11% decrease	NE
119/ docrosco	
11% decrease	14% decrease
NC	NE
NC	NE
NC at TPM doses up to 400 mg/day	13% decrease
ased 25% in some patients, coin.	generally those on a twice a
	NC NC at TPM doses up to 400 mg/day ased 25% in some patients,

In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate tablets has been associated with hyperammonemia with and without encephalopathy and hypothermia [see Warnings and Precautions (5.10), (5.12) and Drug Interactions (7.1)]. CNS Depressants

Concomitant administration of topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate tablets to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate tablets should be used with extreme caution if used in combination with alcohol and other CNS depressants (see Drug Interactions (7.2)).

Oral Contraceptives

Oral Contraceptives In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 15 mg ethniy lestradiol (EE), topitament tablets, golw in the absence of other medications at doses of 50 to200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to ether component of the oral contraceptive. In another study, exposure to EE was statistically significant changes in mean exposure (AUC) to ether component of the oral contraceptive. In another study, exposure to EE was statistically significant day decreased (50 mg/day to 800 mg/day) (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, topiramate tablets (50 mg/day to 800 mg/day) (18%, 21%, and 30%, respectively) whon given as dose-dependent discrease in EE exposure for doses between 200 and 800 mg/day. There was no significant dose-dependent change in EE exposure to to sets hould be consistered in patients taking estrogen-containing contraceptive products with topiramate tablets. Patients taking estrogen-containing contraceptive should be asked or report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding *See Drug Interactions (7.3)*.

Digoxin

In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant topiramate tablets administration. The clinical relevance of this observation has not been established.

Hydrochlorothiazide

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (HCTZ) (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomizanty. The results of this study indicate that topiramate C_{max} increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical aboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination. Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated.

use of metformin is contraindicated. A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin (500 mg every 12 hr) and topiramate in plasma when metformin mass given able and when metformin and topiramate (100 mg every 12 hr) were given simultaneously. The results of this study indicated that the mean metformin Cm₂₀ and AU_{C0,21}, increased by J8%and 25%, respectively, when topiramate was added. Topiramate did not affect metformin thmos, Draf plasma clearance of topiramate appears to be reduced when administered with metformin. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear (see Drug Interactions (7.4)).

Pioglitazone

Poglitazone A drug drug hieraction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pipilizazone when administered alone and concomitantly. A 15% decrease in the AUC_{Carc} of poglitazone when administered alone and C_{maccs} was observed. This finding was not statistically significant. In addition, a 13% and 15% decrease in C_{maccs} and AUC_{Carc} forsectively, of the active hydroxy-metabolit was noted as well as a 60% decrease in C_{maccs} and AUC_{Carc} forsectively. In the active hydroxy-metabolit addet to pipilizazone therapy or pioglitazone is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.

Glyburide

Splin terms of the standard state of the standard state of the standard state of the standard state pharmacokinetics of glyburdle (5 mg/day) alone and concombantly with topiramate (150 mg/day). There was a 22% decises in C_{max} and a 25% reduction in AUC₂₄ for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolics, 4-trans-lydroxy-glyburide (M1) and 3-cs-kydroxyglyburide (M2), was also reduced by 13% and 15%, and C_{max} was reduced by 13% and 25%, respectively. The stady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.

Lithium

In patients, the pharmacokinetics of lithium were unaffected during treatment with Topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (2% for C_{mas} and 26% for AlUC) following topiramate doses up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose topiramate tablets (*geo Drug Interactions (77.5)*). Haloperidol

The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of Topiramate (100 mg every 12 hr) in 13 healthy adults (6 males, 7 females).

Amitriptvline

Anima paymer Anima paymer There was a 12% increase in AUC and C_{max} for ambriptyline (25 mg per day) in 18 normal subjects (9 males, 9 females) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in ambriptyline concentration in the presence of topiramate and any adjustments in ambriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels.

Sumatriptan

Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single-dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).

Risperidone

When administered concomitantly with topiramate tablets at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperitone systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate. No alterations of 9-hydroxyrisperidone levels were observed. Co-administration of topiramate 400 mg/day with specific and 12% increase in AUC1_2 of topiramate. There were not clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone plus 9-hydroxyrisperidone results interase in C_{max} and a 12% increase in AUC1_2 of topiramate. There were not clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone or of topiramate; therefore, this interaction is not likely to be of clinical significance.

Propranolol

Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) idi not affect the pharmacokinetics of propranolol folowing daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate, at a dose of 200 mg/day of topiramate. Dihydroergotamine

Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study. Diltiazem

Co-administration of diltiazem (240 mg Cardizem CD[®]) with topiramate (150 mg/day) resulted in a 10% decrease in C_{max} and a 25% decrease in diltiazem AUC, a 27% decrease in C_{max} and an 13% decrease in des-activ diltiazem AUC, and no effect on N-desmethyl diltiazem. Co-administration of topiramate with diltiazem resulted in a 16% increase in C_{max} and a 13% increase in AUC₂ of topiramate. Venlafaxine

Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg Effexor XR[®]) did not affect the pharmacokinetics of topirama Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic

anhydrase inhibitor (e.g., zonisamide, acetazolamide, or dichlorphenamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, if topfamate tablets is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic acidosis (see Drug Interactions (7.6)).

Drug/Laboratory Tests Interactions

There are no known interactions of topiramate with commonly used laboratory tests

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility

Carcinogenesis

<u>Carcinogenesis</u>. An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady-state exposures in measured in patients receiving Topiramate steady-state texposures in patients receiving 300 mg/kg were approximately 0.5 steady-state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m²

Mutagenesis

Topiramate did not demonstrate genotoxic potential when tested in a battery of *in vitro* and *in vivo* assays. Topiramate was not mutagenic in the Armes test or the *in vitro* mouse hymphoma assay; t did not Increase unscheduled DNA synthesis in rat hepatocytes *in vitro*; and t did not increase chromosomal aberrations in human lymphocytes *in vitro* or in rat bone marrow *in vivo*.

Impairment of Fertility

No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m² basis).

14 CLINICAL STUDIES

The studies described in the following sections were conducted using topiramate tablets 14.1 Monotherapy Epilepsy Controlled Trial


Patients with Partial Onset or Primary Generalized Tonic-Clonic Seizures

Adults and Pediatric Patients 10 Years of Age and Older

The effectiveness of topiramate as initial monotherapy in adults and children 10 years of age and older with partial onset or primary generalized tonic-clonic seizures was established in a multicenter, randomized, double-blind, parallel-group trial.

The trial was conducted in 487 patients diagnosed with pelpesy (6 to 83 years of age) who had 1 or 2 well-documented seizures during the 3-month retrospective baseline phase who then entered the study and received topiramate 25 mg/day for 7 days in an open-label fashion. Forty-nine percent of subjects had no prior AED treatment and 17% had a diagnosis of eplepsy for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior to 50 mg/day or 1400 mg/day. If the target dose could not be achieved, patients were maintained on the mg/day, If the target dose could not be achieved, patients were maintained on the maximum tolerated dose. Fifty-eight percent of patients achieved the maximal dose of 400 mg/day for >2 weeks, and patients who did not tolerate 150 mg/day were discontinued. The primary efficacy assessment was a between-group comparison of time to first seture during the double-bind phase. Comparison of the Kapisa-Meler survival curves of time to first seture favored the topiramate 400 mg/day group over the topiramate 400 mg/day group (s=0.0002, log rank test; Figure 1). The treatment subgroups defined by ages exer, eqoorable region, baseline body weight, baseline seture type, time since diagnosis, and baseline AED use.

Figure 1: Kaplan-Meier Estimates of Cumulative Rates for Time to F



Children 2 to <10 Years of Age

Children 2 to <10 Years of Age The conclusion that topiramate is effective as hitial monotherapy in children 2 to <10 years of age with partial onset or primary generalized tonk-choic secures was based on a pharmacometric bridging approach using data from the controlled epilepsy trials described in labeling. This approach consisted of first showing a similar exposure response relationship between pediatric patients down to 2 years of age and adults when topiramate was given as adjunctive therapy. Similarity of exposure-response was also demonstructed in pediatric patients days 6 to <16 years and adults when topiramate was given as initial monotherapy. Specific dosing in children 2 to <10 years of age was derived from simulations utilizing plasma exposure ranges observed in pediatric and add give ad ministration (2.1)].

14.2 Adjunctive Therapy Epilepsy Controlled Trials

Adult Patients With Partial Onset Seizures

The effectiveness of topiramize as an adjunctive treatment for adults with partial onset secures was established in six multicenter, randomized, double-blind, placebo-controlled trips, two comparing several adages of topiramete and placebo and four comparing single dosage with placebo, in patients with a history of partial onset secures, with or without secondardly generalized secures.

Window securically generated secures. Patients in these studies were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topiramate tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespecified minimum number of partial onset secures, with or without secondary generalization, during the baseline phase (12 secures for 12-week baseline, 8 for 8-week baseline or 3 for 4-week baseline) were randomy assigned to placebo or a specified dose of topiramate tablets in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. In five of Following randomization, patients began the double-bind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week unti the assigned dose was reached, unless intolerance prevented increases. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day initial doses of topiramate were followed by respective avecky increments of 25 or 50 mg/day initial doses of topiramate were followed by respective aptients; randomized to each dose and the actual mean and median doses in the stabilization period are shown in Table 14.

Pediatric Patients Ages 2 to 16 Years with Partial Onset Seizures

The effectiveness of topiranate as an adjunctive treatment for pediatric patients ages 2 to 16 years with partial onset seizures was established in a multicenter, randomized, double-bind, pixeebo-controlled trial comparing topiranate and placebo in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

a nisory of parka truste secures, with or without securically geter adaptive secures. Patients in this activity were permitted a maximum of two antiepleptic drugs (AEDs) in addition to topiramate tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs druming an 8-week baseline phase. Patients who experienced at least six partial onset seizures, with or without secondarily generalized seizures, during the baseline phase were randomly assigned to placebo or topiramate tablets in addition to their other AEDs.

topramate tablets in addition to their other ALDS. Following randomization, patients began the double-bilind phase of treatment. Patients received active drug beginning at 25 or 50 mg/day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225, or 400 mg/day increments every other week until the assigned dosage of 25, 175, 226, and unless htolarence prevented increases. After thration, patients entered an 8-week stabilization period.

Patients With Primary Generalized Tonic-Clonic Seizures

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-choir seizures in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of Topiramate and placebo.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topiramate or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 5-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic setures during the baseline phase were randomly assigned to placebo or topiramate in addition to their other AEDs.

assigned to placebo or topramate in addition to ther onter ALUS. Following randomization, patients began the double-bind phase of treatment. Patients received active drug beginning at 50 mg/day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg/day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.

Patients With Lennox-Gastaut Syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennov-Castaut syndrome was established in a multicenter, randomized, double-bind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 2 years of age and older.

2 years of age and older. Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to Topiramate or placebo. Patients who were experiencing at least 60 seizures per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or topiramate tablets in addition to their other AEDs. Active drug was thrate beginning at 1 mg/kg/day for a week; the dose was then increased to 3 mg/kg/day for one week, then to 6 mg/kg/day. After thration, patients entered an 8week stabilization period. The primary measures of defectiveness were the percent reduction in drop attacks and a parental global rating of seizure severity.

Table14:Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Add-On Trials in Adults with Partial Onset Seizures*

			Targe	t Topira	nmate D	osage(mg/day)
rotoco	Stabilization Dose	Placebo [†]	200	400	600	800	1,000
	N	42	42	40	41		
YD							
	MeanDose	5.9	200	390	556		
	Median Dose	6.0	200	400	600		
YE	N	44			40	45	40
	MeanDose	9.7			544	739	796
	Median Dose	10.0			600	800	1,000
Y1	N	23		19			
	MeanDose	3.8		395			
	Median Dose	4.0		400			
Y2	N	30			28		
	MeanDose	5.7			522		
	Median Dose	6.0			600		
Y3	N	28				25	
	MeanDose	7.9				568	
	Median Dose	8.0				600	
119	N	90	157				
	MeanDose	8	200				
	Median Dose	8	200				

Dosensponse subur. And interimeterimeter of other interesting of proceedings of proceedings of the second se

In all add-on trials, the reduction in seizure rate from baseline during the entire doublebilind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 15. As described above, a global improvement in seizure severity was also assessed in the Lennov-Gastaut trial.

Table 15: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Epilepsy Trials

			Ta	rget 1	opira	mate	Dosa	ge (mg/day)
Protocol Efficacy Re	sults	Placebo	200	400	600	800	1,000	≈6 mg/kg/day
	C	omparisor	ns wit	h place	ebo:			
Partial Onset Seizures		1	I	1	1	1	1	
Studies in Adults								
YD	N	45	45	45	46			
Median % Reduction		11.6	27.2	47.5 [‡]	44.75			
% Responders		18	24	441	46¶			
YE	N	47			48	48	47	
Median % Reduction		1.7			40.85	41.0 [§]	36.0 [§]	
% Responders		9			40 [§]	415	361	
Y1	N	24		23				
Median % Reduction		1.1		40.7#				
% Responders		8		351				
Y2	N	30			30			
Median % Reduction		-12.2			46.4 ^Þ			
% Responders		10			47§			
Y3	N	28				28		
Median % Reduction		-20.6				24.3§		
% Responders		0				43 [§]		
119 N		91	168					
Median % Reduction		20.0	44.2 [§]					
% Responders		24	45 [§]					
Studies in Pediatric Pat	ients							
YP	N	45						41
Median % Reduction		10.5						33.1 [¶]
% Responders		20						39
Primary Generalized To Clonic ^B	nic-							
YTC	N	40						39
Median % Reduction		9.0						56.7 [¶]
% Responders		20						56§
Lennox-Gastaut Syndr	omeà							
YL	N	49						46
Median % Reduction		-5.1						14.8¶
% Responders		14						28è
Improvement in Seizur	e Severity	28						52¶
*For Protocols YP and								
assigned based on sul								

assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; the dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day. \bar{p} =0.080; \bar{p} =0.010;

[§] p≤0.001;
¶p≤0.050;
#p=0.065;
^b p≤0.005;
^B Median % reduction and % responders are reported for PGTC Seizures;
^a Median % reduction and % responders for drop attacks, i.e., tonic or atonic seizures;

Precident 7s resultant and 7s responders for any search responders to the programmer of the search responders and the sear

Subset analyses of the antiepleptic efficacy of topiramate tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

In clinical trials for epilepsy, daily dosages were decreased in weekly intervals by 50 to 100 mg/day in adults and over a 2- to 8-week period in children; transition was permitted to a new antiepileptic regimen when clinically indicated.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Topiramate tablets USP

Topiramate tablets USP are available in the following strengths and colors:

100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side and are available in Bottles of 30's (NDC 63187-696-30)

Bottles of 60's (NDC 63187-696-60)

Bottles of 90's (NDC 63187-696-90)

PHARMACIST: Dispense in a tight container as defined in the USP. Use child-resistant

16.2 Storage a nd Handling

Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature]. Protect from moisture

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Eve Disorders

Instruct patient taking topiramate tablets should be told to seek immediate medical attention if they experience blurred vision, visual disturbances, or periorbital pain [see Warnings and Precautions (5.1), (5.2)].

Oligohidrosis and Hyperthermia

Closely monitor topiramate tablets-treated pateints, especially pediatric patients, for evidence of decreased sweating and increased body temperature, especially in hot weather. Counsel patient to contact their healthcare professionals immediately if they develop a high or persistent fever, or decreased sweating *(see Warnings and Precautions (5.3))*.

Metabolic Acidosis

Warn patients about the potential significant risk for metabolic acidosis that may be asymptomatic and may be associated with adverse effects on kidneys (e.g., kidney stones, nephrocalinosis), bones (e.g., osteporosis, osteomatica, and/or rikets in children), and growth (e.g., growth delay/retardation in pediatric patients, and on the fust (see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)).

Suicidal Behavior and Ideation

Coursel patients, their caregivers, and families that AEDs, including topiramate tablets, may increase the risk of suicidal thoughts and behavior, and advise of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about set-fharm. Instruct patients to immediately report behaviors of concern to their healthcare providers [see Warnings and Precautions (5.5)].

Interference with Cognitive and Motor Performance

Warn patients about the potential for somnolence, dizziness, confusion, dfficulty concentrating, or visual effects, and advice patients not to drive or operate machinery unit they have gained sufficient experience on topiramate tablest to gauge whether it adversely affects their mental performance, motor performance, and/or vision [see Warnings and Precautions (5.6)].

Warnings and Precautions (5.6), Even when taking topiramate tablets other anticonvulsants, some patients with epilepsy will continue to have unpredictable seizures. Therefore, advise all patients taking topiramate tablets for opilepsy to exercise appropriate caution when engaging in any activities where loss of consciousness could result in serious danger to themselves or those around hem (including summing, driving a car, climbing in high paces, etc.). Some patients with refractory epilepsy will need to avoid such activities atogether. Discuss the appropriate level of caution with patients, before patients with epilepsy engage in such activities.

Fetal Toxicity

Feta ToxKEV Inform pregnant women and women of childbearing potential that use of topiramate tablets during pregnancy can cause fetal harm, including an increased risk for cleft lip and/or cleft palate (oral clefts), which occur early in pregnancy before many women know they are pregnant. There may also be risks to the fetus from chronic metabolic acidosis with use of Topiramateduring pregnancy (see Warnings and Precaudions (5.7) and Use in Specific Populations (8.1), (8.9). When appropriate, coursed pregnant work of the present of the presence of the

Advise women of hildbearing potential who are not planning a pregnancy to use effective contraception while using topitramate tablets, keeping in mind that there is potential for decreased contraceptive efficacy when using estrogen-containing birth control with topiramate [see Drug Interactions (7.3)].

cuntor wan topramate (see Drug Interactions (7.3)). Encourage pregnant women using topramate tablets, to enroll in the North American Antipelipetic Drug (INAED) Pregnancy Registry. The registry is collecting information about the safety of antieplipatic drugs during pregnancy. To enrol, patients can call the Pregnancy Registry can be found at http://www.massgeneral.org/aed/ (see Use in Specific Populations (8.1)).

Hyperammonemia and Encephalopathy

Hyperammonema and Encephaopathy Warn patients about the possible development of hyperammonemia with or without encephalopathy. Although hyperammonemia may be asymptomatic, chinal symptoms of hyperammonemic encephalopathy often include acuta alterations in level of consciousness and/or cognitive function with lethargy or vomiting. This hyperammonemia and encephalopathy can develop with topiramate tables treatment alone or with topiramate tables treatment with concomitant valproic acid (VPA).

Kidney Stones

Instruct patients, particularly those with predisposing factors, to maintain an adequate fluid intake in order to minimize the risk of kidney stone formation [see Warnings and Precautions (5.11)].

Instructions for a Missing Dose

Instruct patients that if they miss a single dose of topramate tablets, it should be taken as soon as possible. However, if a patient is within 6 hours of taking the next scheduled dose, tell the patient to wait until then to take the usual dose of topramate tablets, and to skip the missed dose. Tell patients that they should not take a double dose in the event of a missed dose. Advise patients to contact their heathcare provider if they have missed more than one dose.

Manufactured by:

Cipla Ltd, Kurkumbh, India

Manufactured for:

Cipla USA, Inc. 9100 S. Dadeland Blvd., Suite 1500 Miami,

Elorida 33156

Revised on: 1/2015

Medication Guide TOPIRAMATE TABLETS. USP

Read this Medication Guide before you start taking topiramate tablets and each time you get a refit. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about topiramate tablets, tak to your healthcare provider or pharmackt.

What is the most important information I should know about topirar tablets?

Topiramate tablets may cause eye problems. Serious eye problems include:

any sudden decrease in vision with or without eve pain and redness

a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma).

These eye problems can lead to permanent loss of vision if not treated.

You should call your healthcare provider right away if you have any new eye symptoms, including any new problems with your vision.

Topiramate tablets may cause decreased sweating and increased body temperature (fever).

People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition. Call your heathcare provider right away if you have a high fever, a fever that does not go away, or decreased sweating.

ubes not go away, of user teased sweathy. Topiramate tablets may increase the level of acid in your blood (metabolic acidosis). If left untreated, metabolic acidosis can cause brittle or soft bones (osteoporosis, osteomalacia, osteopenia), kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms. Sometimes people with metabolic acidosis will:

feel tired

el changes in heartbeat

have trouble thinking clearly

Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with topiramate tablets. If you are pregnant, you should talk to your healthcare provider about whether you have metabolic acidosis

Like other antiepileptic drugs, topiramate tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

thoughts about suicide or dying

attempts to commit suicide

ew or worse depression

new or worse anxiety

feeling agitated or restless

panic attacks

trouble sleeping (insomnia)

new or worse irritability

acting aggressive, being angry, or violent

acting on dangerous impulses

an extreme increase in activity and talking (mania)

other unusual changes in behavior or mood

D not stop topiramate tablets without first talking to a healthcare provider.

Stopping topiramate tablets suddenly can cause serious problems

Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.

can I watch for early symptoms of suicidal thoughts and actions?

Pay attention to any changes, especially sudden changes, in mood, behaviors thoughts, or feelings

Keep all follow-up visits with your healthcare provider as scheduled.

Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

Topiramate tablets can harm your unborn baby.

If you take topiramate tablets during pregnancy, your baby has a higher risk for birth defects called cleft lip and cleft palate. These defects can begin early in pregnancy, even before you know you are pregnant.

Cleft lip and cleft palate may happen even in children born to women who are not taking any medicines and do not have other risk factors.

There may be other medicines to treat your condition that have a lower chance of birth defects.

All women of childbearing age should talk to their heathcare providers about using other possible treatments instead of topiramate tablets. If the decision is made to use topiramate tablets, you should use effective birth control (contraception) unless you are planning to become pregnant. You should talk to your doctor about the best kind of birth control to use while you are taking topiramate tablets.

Tell your healthcare provider right away if you become pregnant while taking topiramate tablets. You and your healthcare provider should decide if you will continue to take topiramate tablets while you are pregnant.

Metabolic acidosis may have harmful effects on your baby. Talk to your healthcare provider if topiramate tablets has caused metabolic acidosis during your pregnancy.

Pregnancy Registry: If you become pregnant while taking topiramate tablets, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enrol in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy

What is topiramate tablets ?

Topiramate tablets is a prescription medicine used:

to treat certain types of seizures (partial onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older,

with other medicines to treat certain types of seizures (partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox Gastaut syndrome) in adults and children 2 years and older.

What should I tell my healthcare provider before taking topiramate tablets? Before taking topiramate tablets, tell your healthcare provider about all your medical conditions, including if you:

have or have had depression, mood problems, or suicidal thoughts or behavior

have kidney problems, have kidney stones, or are getting kidney dialysis

have a history of metabolic acidosis (too much acid in the blood)

have liver problems

have weak, brittle, or soft bones (osteomalacia, osteoporosis, osteopenia, or decreased bone density)

have lung or breathing problems

have eye problems, especially glaucoma

have diarrhea

have a growth problem

are on a diet high in fat and low in carbohydrates, which is called a ketogenic diel

e having surgery

are pregnant or plan to become pregnant

are breastfeeding. Topiramate tablets passes into breast milk. It is not known if the topiramate that passes into breast milk can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take topiramate tablets.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vtamins, and herbal supplements. Topiramate tablets and other medicines may affect each other causing side effects.

Especially tell your healthcare provider if you take:

Valproic acid (such as DEPAKENE or DEPAKOTE)

Any medicines that impair or decrease your thinking, concentration, or muscle coordination

Birth control pills. Topiramate tablets may make your birth control pills less effective. Tell your heathcare provider if your menstrual bleeding changes while you are taking birth control pills and topiramate tablets.

Ask your healthcare provider if you are not sure if your medicine is listed above Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacst each time you get a new medicine. Do not start a new medicine without taking with your healthcare provider.

How should I take topiramate tablets

Take topiramate tablets exactly as prescribed.

Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.

Topiramate tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.

Topiramate tablets can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent kidney stones while taking topiramate

If you take too much topiramate tablets, call your healthcare provider or poison control center right away or go to the nearest emergency room.

If you miss a single dose of topiramate tablets, take it as soon as you can. However, if you are within 6 hours of taking your next scheduled dose, wait until then to take your usual dose of topiramate tablets, and skip the missed dose. Do not double your dose. If you have missed more than one dose, you should call your healthcare provider for advice.

Do not stop taking topiramate tablets without talking to your healthcare provider. Stopping topiramate tablets suddenly may cause serious problems. If you have epilepsy and you stop taking topiramate tablets suddenly, you may have seizures that do not stop. Your healthcare provider will tell you how to stop taking their term the the forwise. s slowly

Your healthcare provider may do blood tests while you take topiramate tablets.

What should I avoid while taking topiramate tablets ?

What are the possible side effects of topiramate tablets? Topiramate tablets may cause serious side effects including:

Dizziness or loss of muscle coordination.

The most common side effects of topiramate tablets include: tingling of the arms and legs (paresthesia)

when topirar DEPAKOTE).

confusion, or coma.

not feeling hungry

a change in the way foods taste

nausea

Do not drink akohol while taking topiramate tablets.Topiramate tablets and akohol can affect each other causing side effects such as sleepiness and dizziness.

Do not drive a car or operate heavy machinery until you know how topiramate tablets affects you. Topiramate tablets can slow your thinking and motor skills, and may affect vision.

See "what is the most important information i should know about topiramate tablets?" High blood ammonia levels. High ammonia in the blood can affect your mental activities, slow your alertness, make you feel tired, or cause vomiting. This has happened when topiramate tablets is taken with a medicine called valprok actid (DEPAKENE and

 Kidney stones. Drink plenty of fluids when taking topiramate tablets to decrease your chances of getting kidney stones. Low body temperature. Taking topiramate tablets when you are also taki valproic acid can cause a drop in body temperature to less than 95°F, feeling tired

Effects on thinking and alertness. Topiramate tablets may affect how you think and cause confusion, problems with concentration, attention, memory, or speech. Topiramate tablets may cause depression or mood problems, tiredness, and sleepiness.

Call your healthcare provider right away if you have any of the symptoms above.

diarrhea

weight loss

nervousness

upper respiratory tract infection

speech problems

tiredness

dizzines

sleepiness/drowsiness

slow reactions

difficulty with memory

pain in the abdomen

fever

abnormal vision

Tell your healthcare provider about any side effect that bothers you or that does not go away.

Store topiramate tablets USP at room temperature, 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature].

Keep topiramate tablets and all medicines out of the reach of children.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use topiramate tablets for a condition for which it was not prescribed. Do not give topiramate tablets to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about topiramate tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about topiramate tablets that is written for health professionals.

nate tablets?

Tablets - Tablets - contain hypromelose, lactose monohydrate, magnesium stearate, microcrystalline celulose, polyethylene glycol, polysorbate 80, pregelatinzed starch, sodium starch glycolate and ttahum dioxide. In addition, the 25 mg also contains FDGC Blue #2; the 50 mg and 100 mg also contain red iron oxide and yellow iron oxide; and the 200 mg also contains red iron oxide.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

NDC 63187-696-90 Packaged By: Proficient Rx LP Thousand Cake, CA 91323

Topiramate 100mg #90 Tablets SN# MASTER Lot # 00000 Exp 000000 NDC 63107 496.90

Topiramate 100mg #90 Tablets SN# MASTER Lat # 00000 Exp 000000 NDC 43107.4845.90 Topiramate 100mg #90 Tablets SN# MASTER Lof #00000 Exp 000000 NDC 63107-696-60

GTIN: 0036318 SN# MASTER Exp. 00/00/00 Lot # 00000

NDC:63187-696(NDC:69097-124)

Basis of Strength Streng TOPIRAMATE 100 mg

RX Only

Cipla USA, Inc., 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Scan Here

Keep medication out of the reach of children

HUMAN PRESCRIPTION Item Code DRUG (Source)

Comparison of the second definition of units to each patient:
 Depresent the enclosed definition of units to each patient:
 Each film-coated tablet contains: Topiramate USP
 Topirage obtains of circuit: Above, film coated tablet, debeased with "124" on
 one state and "200" on the other activity.

Active Ingredient/Active Moiety Ingredient Name TOPIRAMATE (UNII: 0H73WJJ391) (TOPIRAMATE - UNIE0H73WJJ391)

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Cipla Ltd. at 1-866-604-3268

Keep topiramate tablets in a tightly closed container. Keep topiramate tablets dry and away from moisture.

General information about topiramate tablets

For more information, call 1-866-604-3268 What are the ingredients in topira

Proficient Rx LP Thousand Oaks, CA 91320

ProficientRx

Product ID: PT069690 Mfr. By: Cipla Ltd., Kurkumbh, India Store at 20*-25*C (68*-77*F)

TOPIRAMATE Product Information

Product Type Route of Administration

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Active ingredient: Topiramate USP Inactive ingredients:

Manufactured by: Cipla Ltd Kurkumbh, India Manufacture for:

Repackaged by:

Revised: 1/2015

Rx only NDC 63187-696-90 Topiramate Tablets, USP 100mg PHARMACIST: Dispense the enclosed Medication Guide to each patient. 90 Tablets (Orange)

How should I store topiramate tablets

These are not all the possible side effects of topiramate tablets. For more information, ask your healthcare provider or pharmacist.

			Ingredient I	lame			Strength
		YDRATE (UNII: EW	Q57Q8I5X)				
	ARCH, CORN (UI						
		E CELLULOSE (
		SLYCOLATE TYPE		II: 5856J3G2A	2)		
		RATE (UNII: 7009)					
		910 (3 MPA.S) (
		910 (6 MPA.S) (0 (UNII: 15FIX9V2IP		(0)			
		LYCOL 400 (UNII:					
		(UNII: 60ZP39ZG					
		LOW (UNII: EX438					
		(UNI: 1K09F3G6					
Pr	oduct Chara	cteristics					
		ORANGE			Score		no score
Co							
Co Sh	ape	ROUND (Circular	, biconvex)		Size		9mm
Sh		ROUND (Circular	, biconvex)		Size Imprint Code		9mm 124;Cipla
Sh Fla Co	ape vor ntains	ROUND (Circular	, biconvex)				
Sh Fla Co Pa	ape vor ntains ickaging					Ma	
Sh Fla Co	ape vor ntains		, biconvex) age Descripti	on	Imprint Code	Ма	124;Cipla
Sh Fla Co Pa	vor ntains ckaging Item Code NDC:63187-696- 30	Pack 30 in 1 BOTTLE; Product	age Descripti Type 0: Not a Co	mbination	Imprint Code Marketing Start	Ма	124;Cipla
Sh Fla Co Pa # 1	vor ntains ckaging Item Code NDC:63187-696- 50	Packa 30 in 1 BOTTLE; Product 60 in 1 BOTTLE; Product	age Descripti Type 0: Not a Co Type 0: Not a Co	mbination	Imprint Code Marketing Start Date	Ma	124;Cipla
Sh Fla Co Pa # 1	vor ntains ckaging Item Code NDC:63187-696- 50	Packs 30 in 1 BOTTLE; Product 60 in 1 BOTTLE;	age Descripti Type 0: Not a Co Type 0: Not a Co	mbination	Imprint Code Marketing Start Date 05/02/2016	Ma	124;Cipla
Sh Fla Co Pa # 1	ape vor ntains ickaging item Code NDC:63187-696- 50 NDC:63187-696- 50 NDC:63187-696- 50	Packi 30 in 1 BOTTLE; Product 60 in 1 BOTTLE; Product 90 in 1 BOTTLE;	age Descripti Type 0: Not a Co Type 0: Not a Co	mbination	Marketing Start Date 05/02/2016 05/02/2016	Ma	124;Cipla
Sh Fla Co Pa # 1	ape vor ntains item Code NDC:63187-696- 30 NDC:63187-696- 30 NDC:63187-696- 30	Pack. 30 in 1 BOTTLE; Product 60 in 1 BOTTLE; Product 90 in 1 BOTTLE; Product	age Descripti Type 0: Not a Co Type 0: Not a Co Type 0: Not a Co	mbination	Marketing Start Date 05/02/2016 05/02/2016	Ma	124;Cipla
Sh Fla Co Pa # 1	ape vor ntains item Code NDC:63187-696- 30 NDC:63187-696- 30 NDC:63187-696- 30 NDC:63187-696- 30 NDC:63187-696- 30	Packa 30 in 1 BOTTLE; Product 90 in 1 BOTTLE; Product Informatic	age Descripti Type 0: Not a Co Type 0: Not a Co Type 0: Not a Co	mbination	Imprint Code Marketing Start Date 05/02/2016 05/02/2016 05/02/2016		124;Cipla arketing End Date
Sh Fla Co Pa # 1	ape vor ntains item Code NDC:63187-696- 30 NDC:63187-696- 30 NDC:63187-696- 30	Packa 30 in 1 BOTTLE; Product 90 in 1 BOTTLE; Product Informatic	age Descripti Type 0: Not a Co Type 0: Not a Co Type 0: Not a Co	mbination	Imprint Code Marketing Start Date 05/02/2016 05/02/2016 05/02/2016		124;Cipla

Revised: 4/2022

Proficient Rx LP